CA2067133A1 - Liposome Microreservoir Composition and Method - Google Patents

Liposome Microreservoir Composition and Method

Info

Publication number
CA2067133A1
CA2067133A1 CA2067133A CA2067133A CA2067133A1 CA 2067133 A1 CA2067133 A1 CA 2067133A1 CA 2067133 A CA2067133 A CA 2067133A CA 2067133 A CA2067133 A CA 2067133A CA 2067133 A1 CA2067133 A1 CA 2067133A1
Authority
CA
Canada
Prior art keywords
liposome
therapeutic compound
composition
vesicle
liposomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2067133A
Other languages
French (fr)
Other versions
CA2067133C (en
Inventor
Francis J. Martin
Martin C. Woodle
Carl Redemann
Ramachandran Radhakrishnan
Annie Yau-Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Francis J. Martin
Martin C. Woodle
Carl Redemann
Ramachandran Radhakrishnan
Annie Yau-Young
Liposome Technology, Inc.
Sequus Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23685679&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2067133(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
US case filed in California Northern District Court litigation https://portal.unifiedpatents.com/litigation/California%20Northern%20District%20Court/case/3%3A02-cv-05524 Source: District Court Jurisdiction: California Northern District Court "Unified Patents Litigation Data" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Francis J. Martin, Martin C. Woodle, Carl Redemann, Ramachandran Radhakrishnan, Annie Yau-Young, Liposome Technology, Inc., Sequus Pharmaceuticals, Inc. filed Critical Francis J. Martin
Publication of CA2067133A1 publication Critical patent/CA2067133A1/en
Application granted granted Critical
Publication of CA2067133C publication Critical patent/CA2067133C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5537—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom the heteroring containing the structure -C(=O)-N-C(=O)- (both carbon atoms belong to the heteroring)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

A liposome composition for extended release of a therapeutic compound into the bloodstream. The liposomes are composed of vesicle-forming lipids and between l-20 mole percent of a vesicle-forming lipid derivatized with hydrophilic polymer, have sizes in a selected size range between 0.1 and 0.4 microns, and contain the therapeutic compound in liposome-entrapped form. The dosage form of the composition contains at least about three times the dose of the compound required for intravenous injection in free form. Also disclosed is a method for extending to at least 24 hours the period in which an intravenously administered therapeutic compound is therapeutically active in the blood-stream, and novel liposomes for practicing the method.
CA002067133A 1989-10-20 1990-10-19 Liposome microreservoir composition and method Expired - Lifetime CA2067133C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/425,224 US5013556A (en) 1989-10-20 1989-10-20 Liposomes with enhanced circulation time
US425,224 1989-10-20

Publications (2)

Publication Number Publication Date
CA2067133A1 true CA2067133A1 (en) 1991-04-21
CA2067133C CA2067133C (en) 1998-07-21

Family

ID=23685679

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002067133A Expired - Lifetime CA2067133C (en) 1989-10-20 1990-10-19 Liposome microreservoir composition and method
CA002067178A Expired - Lifetime CA2067178C (en) 1989-10-20 1990-10-19 Solid tumor treatment method and composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002067178A Expired - Lifetime CA2067178C (en) 1989-10-20 1990-10-19 Solid tumor treatment method and composition

Country Status (18)

Country Link
US (2) US5013556A (en)
EP (2) EP0496835B1 (en)
JP (4) JP2667051B2 (en)
KR (2) KR0134982B1 (en)
AT (2) ATE122229T1 (en)
AU (2) AU642679B2 (en)
CA (2) CA2067133C (en)
DE (3) DE69019366T2 (en)
DK (1) DK0496835T3 (en)
ES (1) ES2071976T3 (en)
FI (2) FI921763A0 (en)
GR (1) GR3017060T3 (en)
HK (1) HK14097A (en)
IL (2) IL96069A (en)
LU (1) LU88854I2 (en)
NL (1) NL960031I2 (en)
NO (3) NO304637B1 (en)
WO (2) WO1991005546A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) * 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US6673364B1 (en) 1995-06-07 2004-01-06 The University Of British Columbia Liposome having an exchangeable component
US6734171B1 (en) 1997-10-10 2004-05-11 Inex Pharmaceuticals Corp. Methods for encapsulating nucleic acids in lipid bilayers
US10758329B1 (en) 2019-08-20 2020-09-01 Raymond L. Wright, III Hydrating mouth guard

Families Citing this family (1591)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5456663A (en) * 1984-05-25 1995-10-10 Lemelson; Jerome H. Drugs and methods for treating diseases
US5882330A (en) * 1984-05-25 1999-03-16 Lemelson; Jerome H. Drugs and methods for treating diseases
US5925375A (en) * 1987-05-22 1999-07-20 The Liposome Company, Inc. Therapeutic use of multilamellar liposomal prostaglandin formulations
JPH0720857B2 (en) * 1988-08-11 1995-03-08 テルモ株式会社 Liposome and its manufacturing method
US6132763A (en) * 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
GB8824593D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
US5153000A (en) * 1988-11-22 1992-10-06 Kao Corporation Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US20010051183A1 (en) * 1989-10-20 2001-12-13 Alza Corporation Liposomes with enhanced circulation time and method of treatment
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5843473A (en) * 1989-10-20 1998-12-01 Sequus Pharmaceuticals, Inc. Method of treatment of infected tissues
US5620689A (en) * 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5922304A (en) 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US5705187A (en) * 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5469854A (en) * 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5656211A (en) * 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US5441746A (en) * 1989-12-22 1995-08-15 Molecular Bioquest, Inc. Electromagnetic wave absorbing, surface modified magnetic particles for use in medical applications, and their method of production
US6146657A (en) 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5305757A (en) * 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US6001335A (en) * 1989-12-22 1999-12-14 Imarx Pharmaceutical Corp. Contrasting agents for ultrasonic imaging and methods for preparing the same
US5773024A (en) * 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5352435A (en) * 1989-12-22 1994-10-04 Unger Evan C Ionophore containing liposomes for ultrasound imaging
US5776429A (en) * 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US5882678A (en) * 1990-01-12 1999-03-16 The Liposome Co, Inc. Interdigitation-fusion liposomes containing arachidonic acid metabolites
US5162361A (en) * 1990-04-10 1992-11-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Method of treating diseases associated with elevated levels of interleukin 1
US6465188B1 (en) * 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
US20060084797A1 (en) * 1990-06-11 2006-04-20 Gilead Sciences, Inc. High affinity TGFbeta nucleic acid ligands and inhibitors
US20030113369A1 (en) * 1991-01-16 2003-06-19 Martin Francis J. Liposomes with enhanced circulation time and method of treatment
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5874062A (en) * 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
JP3220180B2 (en) * 1991-05-23 2001-10-22 三菱化学株式会社 Drug-containing protein-bound liposomes
GB9111611D0 (en) * 1991-05-30 1991-07-24 Sandoz Ltd Liposomes
DE69333434T2 (en) 1992-04-03 2005-03-03 The Regents Of The University Of California, Oakland SELF-ORGANIZING SYSTEM FOR THE ADMINISTRATION OF POLYNUCLEOTIDES CONTAINING AN AMPHIPHATIC PEPTIDE
ZA933926B (en) * 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
DK0656368T4 (en) * 1992-08-05 2003-09-29 Meito Sangyo Kk Small diameter composite material containing a water-soluble carboxypolysaccharide and magnetic iron oxide
NL9201722A (en) * 1992-10-05 1994-05-02 Stichting Tech Wetenschapp Pharmaceutical composition for the site-bound release of a clot dissolving protein and method for its preparation.
DE4236237A1 (en) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, their preparation and use as medicines
US6764693B1 (en) * 1992-12-11 2004-07-20 Amaox, Ltd. Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
JP3351476B2 (en) * 1993-01-22 2002-11-25 三菱化学株式会社 Phospholipid derivatives and liposomes containing the same
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
WO1994021281A1 (en) * 1993-03-23 1994-09-29 Liposome Technology, Inc. Polymer-polypeptide composition and method
US6326353B1 (en) * 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
US6180134B1 (en) * 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
WO1994026251A1 (en) * 1993-05-07 1994-11-24 Sequus Pharmaceuticals, Inc. Subcutaneous liposome delivery method
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US20050181976A1 (en) * 1993-05-10 2005-08-18 Ekwuribe Nnochiri N. Amphiphilic oligomers
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
WO1994027580A1 (en) * 1993-05-21 1994-12-08 The Liposome Company, Inc. Reduction of liposome-induced adverse physiological reactions
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
WO1995011670A1 (en) * 1993-10-25 1995-05-04 The Liposome Company, Inc. Liposomal defensins
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5468499A (en) * 1993-11-15 1995-11-21 Ohio State University Liposomes containing the salt of phosphoramide mustard and related compounds
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
JPH09506866A (en) * 1993-12-14 1997-07-08 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン Controlled release of pharmaceutically active substances for immunotherapy
US6312719B1 (en) * 1994-03-04 2001-11-06 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
US6773719B2 (en) * 1994-03-04 2004-08-10 Esperion Luv Development, Inc. Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
US20010055581A1 (en) * 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
US5736121A (en) * 1994-05-23 1998-04-07 Imarx Pharmaceutical Corp. Stabilized homogenous suspensions as computed tomography contrast agents
DE4423131A1 (en) * 1994-07-01 1996-01-04 Bayer Ag New hIL-4 mutant proteins as antagonists or partial agonists of human interleukin 4
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5512294A (en) * 1994-08-05 1996-04-30 Li; King C. Targeted polymerized liposome contrast agents
US6132764A (en) * 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6124439A (en) * 1994-08-17 2000-09-26 The Rockefeller University OB polypeptide antibodies and method of making
DE69527206T2 (en) * 1994-09-30 2003-02-27 Inex Pharmaceuticals Corp AGENT FOR INSERTING POLYANIONIC MATERIALS IN CELLS
ES2153053T3 (en) * 1994-10-14 2001-02-16 Liposome Co Inc LIPOSOMAS OF ETER-LIPIDO AND ITS THERAPEUTIC USE.
CN1080575C (en) * 1994-10-14 2002-03-13 蛋白质传送股份有限公司 Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5827531A (en) * 1994-12-02 1998-10-27 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microcapsules and methods for making
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5830430A (en) * 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
IL112834A (en) * 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
US5658588A (en) * 1995-03-31 1997-08-19 University Of Cincinnati Fibrinogen-coated liposomes
GB9509016D0 (en) * 1995-05-03 1995-06-21 Royal Free Hosp School Med Tissue entrapment
US8071737B2 (en) * 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
US5997898A (en) * 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US6420549B1 (en) 1995-06-06 2002-07-16 Isis Pharmaceuticals, Inc. Oligonucleotide analogs having modified dimers
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en) * 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
DE69634084T2 (en) * 1995-06-07 2005-12-08 Inex Pharmaceuticals Corp. PREPARATION OF LIPID NUCLEIC ACID PARTICLES A HYDROPHOBIC LIPID NUCLEIC ACID COMPLEX INTERMEDIATE PRODUCT AND FOR THE USE IN THE TRANSFER OF THE INVENTION
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US6139819A (en) 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US6033645A (en) * 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
KR19990036033A (en) * 1995-08-01 1999-05-25 한스 루돌프 하우스, 헨리테 브룬너, 베아트리체 귄터 Liposomal Oligonucleotide Compositions
US6051600A (en) * 1995-09-12 2000-04-18 Mayhew; Eric Liposomal hydrolysis-promoting hydrophobic taxane derivatives
US6107332A (en) 1995-09-12 2000-08-22 The Liposome Company, Inc. Hydrolysis-promoting hydrophobic taxane derivatives
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US5858397A (en) * 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
EP0863748A4 (en) * 1995-10-11 1999-11-03 Kevin Jon William Liposomal compositions and methods of using them
US20030040467A1 (en) * 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) * 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US5626654A (en) 1995-12-05 1997-05-06 Xerox Corporation Ink compositions containing liposomes
US5817856A (en) * 1995-12-11 1998-10-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiation-protective phospholipid and method
JP2000503204A (en) 1996-01-08 2000-03-21 ジェネンテック インコーポレーテッド WSX receptor and ligands
US20040014709A1 (en) * 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US5908624A (en) * 1996-06-27 1999-06-01 Albany Medical College Antigenic modulation of cells
USRE39042E1 (en) * 1996-02-16 2006-03-28 The Liposome Company, Inc. Etherlipid-containing multiple lipid liposomes
US5942246A (en) * 1996-02-16 1999-08-24 The Liposome Company, Inc. Etherlipid containing multiple lipid liposomes
US6007839A (en) * 1996-02-16 1999-12-28 The Liposome Company, Inc. Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
US6667053B1 (en) 1996-02-16 2003-12-23 Elan Pharmaceuticals, Inc. D and L etherlipid stereoisomers and liposomes
US5965159A (en) 1996-02-16 1999-10-12 The Liposome Company, Inc. Etherlipid-containing multiple lipid liposomes
CA2250219C (en) 1996-03-28 2008-10-07 Hayat Onyuksel Materials and methods for making improved liposome compositions
EP0935415B1 (en) 1996-05-01 2006-11-22 Imarx Pharmaceutical Corp. In vitro methods for delivering nucleic acids into a cell
WO2005121371A2 (en) * 2004-06-03 2005-12-22 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20050042647A1 (en) * 1996-06-06 2005-02-24 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20070275921A1 (en) * 1996-06-06 2007-11-29 Isis Pharmaceuticals, Inc. Oligomeric Compounds That Facilitate Risc Loading
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US5919480A (en) 1996-06-24 1999-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method
US8007784B1 (en) 1996-06-27 2011-08-30 Albany Medical College Antigenic modulation of cells
US7368129B1 (en) 1996-08-14 2008-05-06 Nutrimed Biotech Amphiphilic materials and liposome formulations thereof
US6284267B1 (en) 1996-08-14 2001-09-04 Nutrimed Biotech Amphiphilic materials and liposome formulations thereof
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
WO1998007409A1 (en) * 1996-08-23 1998-02-26 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
ATE252891T1 (en) 1996-08-26 2003-11-15 Transgene Sa CATIONIC LIPID-NUCLIC ACID COMPLEXES
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
ATE366588T1 (en) * 1996-09-11 2007-08-15 Imarx Pharmaceutical Corp METHOD FOR DIAGNOSTIC IMAGING OF THE KIDNEY REGION USING A CONTRAST AGENT AND A VASODILATOR
US5846517A (en) * 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
US6224903B1 (en) 1996-10-11 2001-05-01 Sequus Pharmaceuticals, Inc. Polymer-lipid conjugate for fusion of target membranes
EP0932390A1 (en) 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
NZ336539A (en) * 1996-10-15 2000-09-29 Liposome Co Inc Peptide-lipid conjugates, liposomes and liposomal drug delivery
US6339069B1 (en) 1996-10-15 2002-01-15 Elan Pharmaceuticalstechnologies, Inc. Peptide-lipid conjugates, liposomes and lipsomal drug delivery
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US20070036722A1 (en) * 1996-10-28 2007-02-15 Pal Rongved Separation processes
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
NZ335596A (en) * 1996-10-28 2000-10-27 Nycomed Imaging As Diagnostic and therapeutic agents comprising microbubbles of a reporter, a surfactant and a vector
US5827533A (en) * 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US6207186B1 (en) * 1997-02-14 2001-03-27 The Regents Of The University Of California Lamellar gels and methods for making and using
US6537246B1 (en) 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US6143276A (en) * 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
HUP0001256A3 (en) 1997-04-03 2002-12-28 Univ Johns Hopkins Med Biodegradable terephthalate polyester-poly(phosphate) polymers, compositions, method for making the same and using them
EP1787999B1 (en) 1997-04-07 2010-08-04 Genentech, Inc. Anti-VEGF antibodies
DK0971959T3 (en) 1997-04-07 2006-05-15 Genentech Inc Humanized antibodies and methods for producing humanized antibodies
WO1998044910A1 (en) * 1997-04-09 1998-10-15 Philipp Lang NEW TECHNIQUE TO MONITOR DRUG DELIVERY NONINVASIVELY $i(IN VIVO)
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
DE69841002D1 (en) * 1997-05-14 2009-09-03 Univ British Columbia Highly effective encapsulation of nucleic acids in lipid vesicles
DE19724796A1 (en) * 1997-06-06 1998-12-10 Max Delbrueck Centrum Antitumor therapy agents
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6663899B2 (en) * 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6217886B1 (en) 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
DE69841598D1 (en) 1997-09-18 2010-05-20 Pacira Pharmaceuticals Inc RETARDANT RELEASE OF LIPOSMAL ANESTHETIC COMPOSITIONS.
US6083923A (en) * 1997-10-31 2000-07-04 Isis Pharmaceuticals Inc. Liposomal oligonucleotide compositions for modulating RAS gene expression
US7229841B2 (en) * 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
CA2309548A1 (en) 1997-11-14 1999-05-27 Skyepharma Inc. Production of multivesicular liposomes
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
EP1481990B1 (en) 1997-11-21 2007-06-06 Genentech, Inc. A-33 related antigens and their pharmacological uses
US6787132B1 (en) * 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
AU756109B2 (en) * 1997-12-04 2003-01-02 Hadasit Medical Research Services & Development Company Ltd Methods for antitumor therapy
EP1947119A3 (en) 1997-12-12 2012-12-19 Genentech, Inc. Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent
US6123923A (en) 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
DK1510579T3 (en) 1998-02-04 2009-11-30 Genentech Inc Use of heregulin as an epithelial cell growth factor
CA2319433C (en) * 1998-02-09 2008-04-22 Bracco Research S.A. Targeted delivery of biologically active media
US6312685B1 (en) 1998-03-13 2001-11-06 Timothy C. Fisher Red blood cells covalently bound with two different polyethylene glycol derivatives
US6942859B2 (en) 1998-03-13 2005-09-13 University Of Southern California Red blood cells covalently bound with polymers
EP1064382B1 (en) 1998-03-17 2008-08-20 Genentech, Inc. Polypeptides homologous to vegf and bmp1
US6433012B1 (en) * 1998-03-25 2002-08-13 Large Scale Biology Corp. Method for inhibiting inflammatory disease
JP2002507567A (en) * 1998-03-25 2002-03-12 ラージ スケール バイオロジー コーポレイション Benzoic acid derivatives for inhibiting angiogenesis
US6858706B2 (en) * 1998-04-07 2005-02-22 St. Jude Children's Research Hospital Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
US6593294B1 (en) * 1998-04-27 2003-07-15 Opperbas Holding B.V. Pharmaceutical composition comprising Factor VIII and neutral liposomes
US6986902B1 (en) * 1998-04-28 2006-01-17 Inex Pharmaceuticals Corporation Polyanionic polymers which enhance fusogenicity
US6448224B1 (en) 1998-05-06 2002-09-10 St. Jude Children's Research Hospital Antibiotics and methods of using the same
US6331407B1 (en) 1998-05-06 2001-12-18 St. Jude Children's Research Hospital Antibiotics and methods of using the same
US6169078B1 (en) * 1998-05-12 2001-01-02 University Of Florida Materials and methods for the intracellular delivery of substances
AU740405B2 (en) 1998-05-15 2001-11-01 Genentech Inc. IL-17 homologous polypeptides and therapeutic uses thereof
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
EP1865061A3 (en) 1998-05-15 2007-12-19 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
EP2058334B1 (en) 1998-06-12 2012-10-31 Genentech, Inc. Monoclonal antibodies, cross-reactive antibodies and method for producing the same
US6726925B1 (en) * 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
US6200598B1 (en) * 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US20040229363A1 (en) * 1998-06-24 2004-11-18 Ed Nolan High efficiency transfection based on low electric field strength, long pulse length
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
ATE428371T1 (en) 1998-07-17 2009-05-15 Pacira Pharmaceuticals Inc BIODEGRADABLE ARRANGEMENTS FOR THE CONTROLLED RELEASE OF ENCLOSED SUBSTANCES
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
CA2346879A1 (en) * 1998-09-16 2000-04-27 Alza Corporation Liposome-entrapped topoisomerase inhibitors
US6077709A (en) 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
US6419709B1 (en) 1998-10-02 2002-07-16 Guilford Pharmaceuticals, Inc. Biodegradable terephthalate polyester-poly(Phosphite) compositions, articles, and methods of using the same
US6153212A (en) * 1998-10-02 2000-11-28 Guilford Pharmaceuticals Inc. Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same
MY126795A (en) 1998-10-23 2006-10-31 Amgen K A Inc Dimeric thrombopoietic peptide mimetics binding to mp1 receptor and having thrombopoietic activity.
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1950300A3 (en) 1998-11-18 2011-03-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
WO2000030628A2 (en) * 1998-11-20 2000-06-02 Genentech, Inc. Method of inhibiting angiogenesis
US6773911B1 (en) 1998-11-23 2004-08-10 Amgen Canada Inc. Apoptosis-inducing factor
EP2075335A3 (en) 1998-12-22 2009-09-30 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
WO2000037502A2 (en) 1998-12-22 2000-06-29 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
US6350464B1 (en) 1999-01-11 2002-02-26 Guilford Pharmaceuticals, Inc. Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
US6818227B1 (en) * 1999-02-08 2004-11-16 Alza Corporation Liposome composition and method for administration of a radiosensitizer
US6537585B1 (en) 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
US6379698B1 (en) 1999-04-06 2002-04-30 Isis Pharmaceuticals, Inc. Fusogenic lipids and vesicles
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US7112337B2 (en) 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
ES2214269T3 (en) * 1999-04-29 2004-09-16 Alza Corporation LIPOSOMIC COMPOSITIONS FOR AN IMPROVED FARMACO RETENTION.
CA2270600A1 (en) 1999-05-03 2000-11-03 Infectio Recherche Inc. Method and formulations for the treatment of diseases, particularly those caused by human immunodeficiency virus and leishmania
EP1645291A1 (en) 1999-05-07 2006-04-12 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
AU4430200A (en) * 1999-05-11 2000-11-21 Sankyo Company Limited Liposome preparation of fat-soluble antitumor drug
US20040229779A1 (en) * 1999-05-14 2004-11-18 Ramesh Kekuda Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20040023874A1 (en) * 2002-03-15 2004-02-05 Burgess Catherine E. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6974684B2 (en) * 2001-08-08 2005-12-13 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20040067490A1 (en) * 2001-09-07 2004-04-08 Mei Zhong Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1978029A3 (en) 1999-06-15 2008-10-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids endoding the same
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
EP1190705A4 (en) * 1999-06-24 2009-03-18 Kyowa Hakko Kogyo Kk Method of regulating leakage of drug encapsulated in liposomes
MXPA01013458A (en) 1999-06-25 2002-07-30 Genentech Inc HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES.
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
GB9918670D0 (en) 1999-08-06 1999-10-13 Celltech Therapeutics Ltd Biological product
KR20090024308A (en) 1999-08-27 2009-03-06 제넨테크, 인크. Dosages for treatment with anti-erbb2 antibodies
KR20050004240A (en) * 1999-08-31 2005-01-12 제넨테크, 인크. Compositions and Methods for the Treatment of Tumor
KR20010085996A (en) * 1999-09-03 2001-09-07 스티븐 엠. 오드레 Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
WO2001026625A2 (en) 1999-10-08 2001-04-19 Alza Corp Neutral-cationic lipid for nucleic acid and drug delivery
IT1315253B1 (en) * 1999-10-22 2003-02-03 Novuspharma Spa LIPOSOMIAL PREPARATION OF 6,9-BIS- (2-AMINOXYL) AMINO | BENZOG | ISOCHINOLIN-5,10-DIONE DIMALEATO
US7067111B1 (en) * 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
EP3225632B1 (en) 1999-11-30 2020-05-06 Mayo Foundation for Medical Education and Research Antibodies binding to b7-h1, a novel immunoregulatory molecule
EP1690872A3 (en) 1999-12-01 2006-08-23 Genentech, Inc. Composition and methods for the diagnosis of tumours
US6593308B2 (en) 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
AU2136501A (en) * 1999-12-10 2001-06-18 Celator Technologies Inc. Lipid carrier compositions with protected surface reactive functions
DK1897945T3 (en) 1999-12-23 2012-05-07 Genentech Inc IL-17 homologous polypeptides and therapeutic uses thereof.
JP2003520210A (en) * 2000-01-05 2003-07-02 イマレックス セラピューティクス， インコーポレイテッド Pharmaceutical formulations for delivery of drugs with low water solubility
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
IL150676A0 (en) * 2000-01-13 2003-02-12 Genentech Inc NOVEL STRa6 POLYPEPTIDES
US20020055479A1 (en) 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
US6261840B1 (en) 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
DK1274399T3 (en) * 2000-01-28 2005-08-08 Alza Corp Liposomes containing an encapsulated compound in supersaturated solution
US20030176385A1 (en) * 2000-02-15 2003-09-18 Jingfang Ju Antisense modulation of protein expression
JP4922824B2 (en) * 2000-04-03 2012-04-25 参天製薬株式会社 Delivery substance and drug delivery system using the same
WO2001077342A1 (en) 2000-04-11 2001-10-18 Genentech, Inc. Multivalent antibodies and uses therefor
DK1272225T3 (en) * 2000-04-12 2006-12-27 Liplasome Pharma As Lipid-based systems for targeted delivery of diagnostic agents
MXPA02010324A (en) 2000-04-21 2003-04-25 Amgen Inc Apo ai aii peptide derivatives.
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
AU2001258106A1 (en) * 2000-05-11 2001-11-20 Celator Technologies Inc. Lipid carrier compositions for improved drug retention
US6680172B1 (en) 2000-05-16 2004-01-20 Regents Of The University Of Michigan Treatments and markers for cancers of the central nervous system
PL212211B1 (en) * 2000-06-02 2012-08-31 Regents Board Of Ethylenedicysteine (ec)-drug conjugates
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030072794A1 (en) * 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
AU6836301A (en) 2000-06-20 2002-01-02 Idec Pharma Corp Treatment of b-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
EP2042597B1 (en) 2000-06-23 2014-05-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2648048A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20040023259A1 (en) * 2000-07-26 2004-02-05 Luca Rastelli Therapeutic polypeptides, nucleic acids encoding same, and methods of use
DE60136281D1 (en) 2000-08-24 2008-12-04 Genentech Inc METHOD FOR INHIBITING IL-22-INDUCED PAP1
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030133972A1 (en) * 2000-10-11 2003-07-17 Targesome, Inc. Targeted multivalent macromolecules
US7045283B2 (en) 2000-10-18 2006-05-16 The Regents Of The University Of California Methods of high-throughput screening for internalizing antibodies
DK2174954T3 (en) 2000-10-18 2016-07-04 Robert Sackstein HEMATOPOIETIC CELL E-selectin / L-SELEKTINLIGAND polypeptides and methods of use thereof
WO2002036073A2 (en) * 2000-11-02 2002-05-10 Smithkline Beecham Corporation Receptor antagonist-lipid conjugates and delivery vehicles containing same
DE10056136A1 (en) * 2000-11-07 2002-05-16 Nemod New Modalities Inhibiting leukocyte or tumor cell adhesion to vascular endothelial cells e.g. for combating inflammation or metastasis, using e.g. pregnancy proteins or selectin binding liposomes containing calcium-binding compound
AU2002248190A1 (en) * 2000-11-30 2002-08-12 The Research Foundation Of State University Of New York Method of complexing a protein by the use of a dispersed system and proteins thereof
US20020132982A1 (en) * 2000-11-30 2002-09-19 Balasubramanian Sathyamangalam V. AHF associated dispersion system and method for preparation
US8110218B2 (en) * 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
US7625584B2 (en) * 2000-11-30 2009-12-01 The Research Foundation Of State University Of New York Method of complexing a protein by the use of a dispersed system and proteins thereof
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
CN1982330B (en) * 2000-12-18 2012-01-25 卡比斯特制药公司 Methods for preparing purified lipopeptides
WO2002059145A1 (en) * 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
US20040077604A1 (en) * 2001-12-19 2004-04-22 Lenard Lichtenberger Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
US6964849B2 (en) 2001-01-11 2005-11-15 Curagen Corporation Proteins and nucleic acids encoding same
US20040043928A1 (en) * 2001-08-02 2004-03-04 Ramesh Kekuda Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
AR035779A1 (en) 2001-02-06 2004-07-14 Genetics Inst Llc FUSION POLYPEPTIDES DERIVED FROM GLICOPROTEIN IB PLATE ALFA AND METHODS OF USE OF THE SAME
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
EP1372739A4 (en) * 2001-03-08 2005-10-19 Targesome Inc Stabilized therapeutic and imaging agents
IL158160A0 (en) * 2001-03-26 2004-03-28 Alza Corp Liposome composition for improved intracellular delivery of a therapeutic agent
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
WO2002087541A1 (en) * 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
EP1383480A4 (en) * 2001-04-30 2006-05-24 Targeted Genetics Corp Lipid-comprising drug delivery complexes and methods for their production
GB0111279D0 (en) * 2001-05-10 2001-06-27 Nycomed Imaging As Radiolabelled liposomes
ATE549354T1 (en) 2001-05-11 2012-03-15 Amgen Inc PEPTIDES AND ASSOCIATED TALL-1 BINDING MOLECULES
WO2002092554A1 (en) * 2001-05-15 2002-11-21 Transgene S.A. Complexes for transferring substances of interest into a cell
AU2002310046A1 (en) * 2001-05-22 2002-12-03 Duke University Compositions and methods for inhibiting metastasis
US20020197253A1 (en) * 2001-05-22 2002-12-26 Cheek Dennis J. Compositions and methods for promoting or inhibiting NDPK
NZ544410A (en) 2001-05-30 2008-04-30 Genentech Inc Anti-ngf antibodies for the treatment of various disorders
AU2002322024B2 (en) * 2001-05-31 2008-05-08 Pacira Pharmaceuticals, Inc. Encapsulation of nanosuspensions in liposomes and microspheres
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
JP2005501011A (en) * 2001-06-08 2005-01-13 ユタ ベンチャー ザ セカンド リミテッド パートナーシップ Tissue-specific inner membrane protein
US20050107595A1 (en) * 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7803915B2 (en) * 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
DK2000545T3 (en) 2001-06-20 2011-11-28 Genentech Inc Compositions and methods for diagnosis and treatment of lung tumor
CA2451643C (en) 2001-06-21 2012-11-13 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
CN1827766B (en) 2001-06-28 2010-08-25 徐荣祥 In vitro cell cultivation method
US20030087274A1 (en) * 2001-07-05 2003-05-08 Anderson David W. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20040029790A1 (en) * 2001-07-05 2004-02-12 Meera Patturajan Novel human proteins, polynucleotides encoding them and methods of using the same
WO2003007914A2 (en) * 2001-07-19 2003-01-30 Guilford Pharmaceuticals, Inc. Biocompatible polymer containing composition for treatment of prostate cancers
WO2003007915A2 (en) * 2001-07-19 2003-01-30 Guilford Pharmaceuticals, Inc. Compositions for treatment of head and neck cancers, and methods of making and using the same
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
US6964950B2 (en) 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
IL160016A0 (en) * 2001-07-29 2004-06-20 Yissum Res Dev Co Osteogenic growth oligopeptides as stimulants of hematopoiesis
US20030096772A1 (en) 2001-07-30 2003-05-22 Crooke Rosanne M. Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US20040030096A1 (en) * 2001-08-02 2004-02-12 Linda Gorman Novel human proteins, polynucleotides encoding them and methods of using the same
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
WO2003015707A2 (en) * 2001-08-20 2003-02-27 Transave, Inc. Method for treating lung cancers
KR20040066788A (en) 2001-08-31 2004-07-27 더 락커펠러 유니버시티 Phosphodiesterase activity and regulation of phosphodiesterase 1b-mediated signaling in brain
US20040235068A1 (en) * 2001-09-05 2004-11-25 Levinson Arthur D. Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7547673B2 (en) * 2001-09-13 2009-06-16 The Johns Hopkins University Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production
EP2174953A1 (en) 2001-09-18 2010-04-14 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7981863B2 (en) 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
DE10148065A1 (en) * 2001-09-28 2003-04-17 Max Planck Gesellschaft (Ester) -lysolecithins in liposomes
WO2003026588A2 (en) * 2001-09-28 2003-04-03 Esperion Therapeutics, Inc. Methods and apparatus for extrusion of vesicles at high pressure
NZ566396A (en) 2001-10-09 2009-07-31 Isis Pharmaceuticals Inc Antisense modulation of insulin-like growth factor binding protein 5 expressions
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
US20030199442A1 (en) * 2001-10-09 2003-10-23 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7332474B2 (en) * 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
IL161733A0 (en) 2001-11-02 2005-11-20 Insert Therapeutics Inc Methods and compositions for therapeutic use of rna interference
WO2003039595A2 (en) * 2001-11-07 2003-05-15 Inex Pharmaceuticals Corporation Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
US20040219201A1 (en) * 2001-12-06 2004-11-04 Yechezkel Barenholz Tempamine compositions and methods of use
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
AU2002367318B2 (en) 2002-01-02 2007-07-12 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP4508645B2 (en) 2002-01-04 2010-07-21 ザ ロックフェラー ユニバーシティー Compositions and methods for the prevention and treatment of amyloid-beta peptide related diseases
US7781396B2 (en) * 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
US20040052928A1 (en) * 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
EP1487273B1 (en) 2002-02-13 2009-01-21 Immunology Laboratories, Inc. Compositions and methods for treatment of microbial infections
WO2003072035A2 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20090042291A1 (en) * 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
US20100311954A1 (en) * 2002-03-01 2010-12-09 Xencor, Inc. Optimized Proteins that Target Ep-CAM
US20030180712A1 (en) 2002-03-20 2003-09-25 Biostratum Ab Inhibition of the beta3 subunit of L-type Ca2+ channels
US20040009216A1 (en) * 2002-04-05 2004-01-15 Rodrigueza Wendi V. Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
JP2005536190A (en) 2002-04-16 2005-12-02 ジェネンテック・インコーポレーテッド Compositions and methods for tumor diagnosis and treatment
EP1517923A2 (en) * 2002-04-22 2005-03-30 Recopharma AB Compositions and methods for inhibiting microbial adhesion
US20040009944A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Methylated immunostimulatory oligonucleotides and methods of using the same
US7199107B2 (en) 2002-05-23 2007-04-03 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
AU2003236521A1 (en) * 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
EP2338478B1 (en) 2002-06-28 2014-07-23 Protiva Biotherapeutics Inc. Method for producing liposomes
AU2003241598B2 (en) * 2002-07-02 2009-11-05 Nanotx Corp. Radiolabeled compounds and liposomes and their methods of making and using the same
AU2003267984A1 (en) * 2002-07-03 2004-01-23 Receptor Biologix, Inc. Liposomal vaccine
US20040247661A1 (en) * 2002-07-03 2004-12-09 Dov Michaeli Liposomal vaccine
US20050169979A1 (en) * 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
EP1572130A4 (en) 2002-07-08 2008-07-02 Genentech Inc Compositions and methods for the treatment of immune related diseases
EP1585966B8 (en) 2002-07-15 2012-03-07 F. Hoffmann-La Roche AG Treatment of cancer with the anti-ErbB2 antibody rhuMAb 2C4
EP1537146B9 (en) * 2002-07-15 2011-07-06 Board Of Regents, The University Of Texas System Antibodies binding to anionic phospholipids and aminophospholipids and their use in treating viral infections
US7625563B2 (en) * 2002-07-15 2009-12-01 Board Of Regents, The University Of Texas System Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids
US7572448B2 (en) * 2002-07-15 2009-08-11 Board Of Regents, The University Of Texas System Combined cancer treatment methods using selected antibodies to aminophospholipids
US7615223B2 (en) * 2002-07-15 2009-11-10 Board Of Regents, The University Of Texas System Selected immunoconjugates for binding to aminophospholipids
US7714109B2 (en) * 2002-07-15 2010-05-11 Board Of Regents, The University Of Texas System Combinations and kits for cancer treatment using selected antibodies to aminophospholipids
US7622118B2 (en) * 2002-07-15 2009-11-24 Board Of Regents, The University Of Texas System Cancer treatment methods using selected antibodies to aminophospholipids
US7678386B2 (en) * 2002-07-15 2010-03-16 Board Of Regents The University Of Texas Liposomes coated with selected antibodies that bind to aminophospholipids
CA2492654A1 (en) * 2002-07-16 2004-01-22 University Of South Florida Human immunosuppressive protein
US20040161423A1 (en) * 2002-07-18 2004-08-19 Sanjeev Kumar (Mendiratta) Polymer modified anti-angiogenic serpins
MXPA05001312A (en) * 2002-08-02 2005-08-03 Transave Inc Platinum aggregates and process for producing the same.
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
AU2003262650B2 (en) 2002-08-14 2009-10-29 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
EP1393720A1 (en) * 2002-08-27 2004-03-03 Universiteit Utrecht Vesicle-encapsulated corticosteroids for treatment of cancer
PL376536A1 (en) 2002-08-28 2006-01-09 Immunex Corporation Compositions and methods for treating cardiovascular disease
AR036316A1 (en) * 2002-08-29 2004-08-25 Monte Verde S A A PHARMACEUTICAL COMPOSITION OF SMALL SIZE LIPOSOMES AND PREPARATION METHOD
US20070231379A1 (en) * 2002-08-29 2007-10-04 Slater James L Liposome-entrapped topoisomerase inhibitors
US7655772B2 (en) 2002-09-06 2010-02-02 University Of South Florida Materials and methods for treatment of allergic diseases
US20050272650A1 (en) * 2004-02-17 2005-12-08 Mohapatra Shyam S Materials and methods for treatment of inflammatory and cell proliferation disorders
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
WO2004024068A2 (en) 2002-09-11 2004-03-25 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
EP1578373A4 (en) 2002-09-11 2007-10-24 Genentech Inc Novel compositions and methods for the treatment of immune related diseases
CN1694959B (en) * 2002-09-13 2013-09-18 雷普利瑟公司 Non-sequence complementary antiviral oligonucleotides
US20050196382A1 (en) * 2002-09-13 2005-09-08 Replicor, Inc. Antiviral oligonucleotides targeting viral families
EP2444409A2 (en) 2002-09-16 2012-04-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
JP2006513700A (en) 2002-09-25 2006-04-27 ジェネンテック・インコーポレーテッド Novel compositions and methods for the treatment of psoriasis
US7229976B2 (en) 2002-09-26 2007-06-12 Isis Pharmaceuticals, Inc. Modulation of forkhead box O1A expression
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
US20040062748A1 (en) * 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20060147450A1 (en) * 2002-10-04 2006-07-06 Shelton David L Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
AU2003304238A1 (en) 2002-10-08 2005-01-13 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
WO2004032870A2 (en) 2002-10-08 2004-04-22 Rinat Neuroscience Corp. Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
EP1633786A4 (en) * 2002-10-09 2007-07-25 Rinat Neuroscience Corp Methods of treating alzheimer s disease using antibodies directed against amyloid beta peptide and compositions thereof
JP2006517785A (en) 2002-10-29 2006-08-03 ジェネンテック・インコーポレーテッド Novel compositions and methods for the treatment of immune related diseases
EP1560597A4 (en) * 2002-10-29 2007-06-27 Pharmacia Corp Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
AU2003290598A1 (en) 2002-11-05 2004-06-03 Isis Pharmaceuticals, Inc. Modified oligonucleotides for use in rna interference
AU2003287505A1 (en) 2002-11-05 2004-06-03 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US20040093198A1 (en) * 2002-11-08 2004-05-13 Carbon Design Systems Hardware simulation with access restrictions
EP1581169A4 (en) 2002-11-08 2008-09-17 Genentech Inc Compositions and methods for the treatment of natural killer cell related diseases
WO2004043396A2 (en) * 2002-11-09 2004-05-27 Nobex Corporation Modified carbamate-containing prodrugs and methods of synthesizing same
CA2505801A1 (en) 2002-11-13 2004-05-27 Rosanne Crooke Antisense modulation of apolipoprotein b expression
ES2420914T3 (en) 2002-11-13 2013-08-27 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US20050158375A1 (en) * 2002-11-15 2005-07-21 Toshikiro Kimura Pharmaceutical composition containing liposomes for treating cancer
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
PL377813A1 (en) 2002-11-26 2006-02-20 Biocon Limited Modified naturetic compounds, conjugates, and uses thereof
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US20070048301A1 (en) 2002-11-26 2007-03-01 Bodary-Winter Sarah C Compositions and methods for the treatment of immune related diseases
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
KR20050090987A (en) * 2002-12-19 2005-09-14 알자 코포레이션 Method of treating angiogenic tissue growth
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
ES2382918T3 (en) 2002-12-24 2012-06-14 Rinat Neuroscience Corp. Anti-NGF antibodies and procedures using them
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
ES2337563T3 (en) 2002-12-31 2010-04-27 Zydus Bsv Pharma Private Limited UNPEGLATED LIPOSOMES OF LASTING CIRCULATION.
US8980310B2 (en) * 2002-12-31 2015-03-17 Bharat Serums and Vaccines, Ltd. Non-pegylated long-circulating liposomes
EP1583713B1 (en) * 2003-01-07 2009-03-25 Ramot at Tel Aviv University Ltd. Peptide nanostructures encapsulating a foreign material and method of manufacturing same
EP1591450A4 (en) * 2003-01-10 2006-05-17 Yamanouchi Pharma Co Ltd Conjugate for retention in blood and cancer tissue-specific drug delivery
US7169892B2 (en) 2003-01-10 2007-01-30 Astellas Pharma Inc. Lipid-peptide-polymer conjugates for long blood circulation and tumor specific drug delivery systems
US7468356B2 (en) 2003-02-11 2008-12-23 Antisense Therapeutics Ltd. Modulation of insulin like growth factor I receptor expression
EP1594441B1 (en) 2003-02-19 2010-12-15 Rinat Neuroscience Corp. Method for treating pain by administering a nerve growth factor antagonist and an nsaid and composition containing the same
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US7968115B2 (en) 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
US20060198882A1 (en) * 2003-03-21 2006-09-07 Yechezkel Barenholz Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
WO2004089339A2 (en) 2003-03-31 2004-10-21 Alza Corporation Lipid particles having asymmetric lipid coating and method of preparing same
PT1610820E (en) 2003-04-04 2010-12-16 Novartis Ag High concentration antibody and protein formulations
WO2004091657A2 (en) 2003-04-09 2004-10-28 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
DK1633440T3 (en) * 2003-04-15 2008-09-08 Opperbas Holding Bv Pharmaceutical composition comprising proteins and / or polypeptides and colloidal particles
WO2004094457A2 (en) * 2003-04-16 2004-11-04 Arizona Board Of Regents, Acting For And On Behalf Of, Arizona State University Stable rgd peptidomimetic composition
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
CA2522184A1 (en) * 2003-04-17 2004-11-04 The Trustees Of Columbia University In The City Of New York Desmoglein 4 is a novel gene involved in hair growth
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
MXPA05012314A (en) 2003-05-12 2006-04-18 Affymax Inc Spacer moiety for poly(ethylene glycol) -modified peptides.
WO2004101600A2 (en) 2003-05-12 2004-11-25 Affymax, Inc. Novel poly(ethylene glycol) modified compounds and uses thereof
CA2526080A1 (en) * 2003-05-30 2005-01-06 Genentech, Inc. Polypeptides that bind an anti-tissue factor antibody and uses thereof
BRPI0411200A (en) 2003-05-30 2006-07-18 Genentech Inc cancer treatment method, human patient treatment methods, industrialized article and cancer treatment kit
WO2005002507A2 (en) 2003-06-03 2005-01-13 Isis Pharmaceuticals, Inc. Modulation of survivin expression
EP1629085A2 (en) * 2003-06-04 2006-03-01 CANJI, Inc. Transfection agents
CA2528343A1 (en) 2003-06-06 2005-01-06 Genentech, Inc. Modulating the interaction between hgf beta chain and c-met
JP2007537710A (en) 2003-06-11 2007-12-27 ワイス Platelet glycoprotein IBα variant fusion polypeptide and use thereof
US7939058B2 (en) * 2003-07-03 2011-05-10 University Of Southern California Uses of IL-12 in hematopoiesis
ATE478963T1 (en) 2003-07-03 2010-09-15 Univ New Jersey Med GENES AS DIAGNOSTIC TOOLS FOR AUTISM
EP2784084B2 (en) 2003-07-08 2023-10-04 Novartis Pharma AG Antagonist antibodies to IL-17A/F heterologous polypeptides
EP1648519B1 (en) * 2003-07-16 2014-10-08 Protiva Biotherapeutics Inc. Lipid encapsulated interfering rna
CN100431525C (en) * 2003-07-17 2008-11-12 台湾东洋药品工业股份有限公司 Production method of liposome suspended liquid and products thereof
CA2533701A1 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
KR20090077984A (en) * 2003-07-31 2009-07-16 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 Sterile preparations of phospholipids and anti-inflammatory pharmaceuticals
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20050043239A1 (en) * 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
WO2005016349A1 (en) * 2003-08-14 2005-02-24 Icos Corporation Methods of inhibiting leukocyte accumulation
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
US8986731B2 (en) * 2003-08-26 2015-03-24 Biolitec Pharma Marketing Ltd Pegylated liposomal formulations of hydrophobic photosensitizers for photodynamic therapy
DE602004019546D1 (en) * 2003-08-26 2009-04-02 Smithkline Beecham Corp HETEROFUNCTIONAL COPOLYMERS OF GLYCEROL AND POLYETHYLENE GLYCOL, ITS CONJUGATES AND COMPOSITIONS
US8846079B1 (en) 2004-12-01 2014-09-30 Vgsk Technologies, Inc. Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
US11324698B2 (en) 2003-08-28 2022-05-10 Vgsk Technologies, Inc. Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
US20060115523A1 (en) * 2004-12-01 2006-06-01 Konduri Kameswari S Sterically stabilized liposome and triamcinolone composition for treating the respiratory tract of a mammal
CN1867580B (en) * 2003-09-03 2010-09-29 协和发酵麒麟株式会社 Compound modified with glycerol derivative
US20050233435A1 (en) * 2003-09-04 2005-10-20 Nyu Medical Center Plasmodium axenic liver stages as a noninfectious whole organism malaria vaccine
US20070123480A1 (en) * 2003-09-11 2007-05-31 Replicor Inc. Oligonucleotides targeting prion diseases
KR101164256B1 (en) * 2003-09-15 2012-07-10 프로티바 바이오쎄라퓨틱스, 인코포레이티드 Polyethyleneglycol-modified lipid compounds and uses thereof
NZ545134A (en) 2003-09-18 2009-06-26 Lilly Co Eli Modulation of eIF4E expression
WO2005027901A1 (en) * 2003-09-25 2005-03-31 Tel Aviv University Future Technology Development L.P. Compositions and methods using same for treating amyloid-associated diseases
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US7625707B2 (en) * 2003-10-02 2009-12-01 Ramot At Tel Aviv University Ltd. Antibacterial agents and methods of identifying and utilizing same
EP1678194B1 (en) 2003-10-10 2013-06-26 Alchemia Oncology Pty Limited The modulation of hyaluronan synthesis and degradation in the treatment of disease
WO2005034979A2 (en) * 2003-10-11 2005-04-21 Inex Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
AU2004283758A1 (en) * 2003-10-24 2005-05-06 Alza Corporation Preparation of lipid particles
WO2005041870A2 (en) 2003-10-24 2005-05-12 Ader Enterprises, Inc. Composition and method for the treatment of eye disease
WO2005040163A1 (en) * 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd Heterocyclic compounds that block the effects of advanced glycation end products (age)
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
WO2005046637A2 (en) * 2003-11-14 2005-05-26 Het Nederlands Kanker Instituut Pharmaceutical formulations employing short-chain sphingolipids and their use
US20050129753A1 (en) * 2003-11-14 2005-06-16 Gabizon Alberto A. Method for drug loading in liposomes
ES2493016T3 (en) 2003-11-17 2014-09-11 Genentech, Inc. Compositions comprising antibodies against CD79b conjugated to a growth inhibitory agent or a cytotoxic agent and methods for the treatment of tumors of hematopoietic origin
US7750123B2 (en) * 2003-11-25 2010-07-06 Dana Farber Cancer Institute, Inc. Antibodies against SARS-CoV and methods of use thereof
EP1701979A2 (en) * 2003-12-03 2006-09-20 Xencor, Inc. Optimized antibodies that target the epidermal growth factor receptor
US9050378B2 (en) * 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
AU2004298483A1 (en) 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
EP2402756A3 (en) * 2003-12-23 2012-02-22 Rinat Neuroscience Corp. Agonist anti-trkC antibodies and methods using same
TR201815885T4 (en) 2004-01-07 2018-11-21 Novartis Vaccines & Diagnostics Inc M-csf specific monoclonal antibodies and their use.
JP2007520481A (en) * 2004-01-15 2007-07-26 アルザ・コーポレーシヨン Liposome composition for delivering therapeutic agents
JP2007520222A (en) 2004-01-20 2007-07-26 アイシス ファーマシューティカルズ インコーポレイテッド Regulation of glucocorticoid receptor expression
US7468431B2 (en) 2004-01-22 2008-12-23 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP2 expression
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
AU2005214382B2 (en) 2004-02-19 2011-08-04 Genentech, Inc. CDR-repaired antibodies
US8784881B2 (en) 2004-03-05 2014-07-22 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
JP4937899B2 (en) * 2004-03-12 2012-05-23 アルナイラム ファーマシューティカルズ， インコーポレイテッド IRNA substances targeting VEGF
EP1579850A3 (en) * 2004-03-15 2009-12-16 Nipro Corporation A pharmaceutical composition containing liposomes for treating a cancer
US8790919B2 (en) 2004-03-15 2014-07-29 Isis Pharmaceuticals, Inc. Compositions and methods for optimizing cleavage of RNA by RNase H
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
CA2559722A1 (en) * 2004-03-18 2005-09-29 Transave, Inc. Administration of cisplatin by inhalation
KR101245990B1 (en) * 2004-03-26 2013-03-20 테루모 가부시키가이샤 Liposome preparation
CA2561221C (en) * 2004-03-26 2016-09-20 Curis, Inc. Rna interference modulators of hedgehog signaling and uses thereof
US20050244869A1 (en) * 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
CA2562024C (en) * 2004-04-07 2014-05-27 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
EP1742660A2 (en) * 2004-04-16 2007-01-17 Genentech, Inc. Treatment of disorders
CA3006109A1 (en) 2004-05-03 2005-11-17 Ipsen Biopharm Ltd. Drug delivery liposomes containing anionic polyols or anionic sugars
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
SI2612862T1 (en) 2004-05-13 2017-04-26 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
AU2005251691A1 (en) * 2004-05-17 2005-12-22 Tekmira Pharmaceuticals Corporation Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
AU2005250369A1 (en) * 2004-05-18 2005-12-15 Genentech, Inc. M13 virus major coat protein variants for C-terminal and BI-terminal display of a heterologous protein
US20050260260A1 (en) * 2004-05-19 2005-11-24 Edward Kisak Liposome compositions for the delivery of macromolecules
JP2008500397A (en) * 2004-05-21 2008-01-10 トランセイブ， インク． Treatment of pulmonary and pre-pulmonary disease states
MXPA06013581A (en) * 2004-05-25 2007-03-15 Metabolex Inc Substituted triazoles as modulators of ppar and methods of their preparation.
EP1755609A1 (en) * 2004-05-25 2007-02-28 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
JP2008500358A (en) * 2004-05-25 2008-01-10 メタボレックス インコーポレーティッド Bicyclic substituted triazoles as modulators of PPARs and methods for their preparation
CA2568249C (en) * 2004-05-28 2014-12-09 Human Biomolecular Research Institute Synthesis of metabolically stable analgesics, pain medications and other agents
AU2004320622B2 (en) * 2004-06-03 2012-06-14 Isis Pharmaceuticals, Inc. Chimeric gapped oligomeric compositions
US20090048192A1 (en) * 2004-06-03 2009-02-19 Isis Pharmaceuticals, Inc. Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
MXPA06014069A (en) 2004-06-04 2007-04-25 Genentech Inc Method for treating multiple sclerosis.
JP4796062B2 (en) * 2004-06-07 2011-10-19 プロチバ バイオセラピューティクス インコーポレイティッド Lipid-encapsulating interfering RNA
AU2005251403B2 (en) 2004-06-07 2011-09-01 Arbutus Biopharma Corporation Cationic lipids and methods of use
CA2579756C (en) * 2004-06-19 2013-04-30 Human Biomolecular Research Institute Modulators of central nervous system neurotransmitters
AU2005258161B2 (en) 2004-06-21 2011-05-26 The Board Of Trustees Of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
WO2006002538A1 (en) 2004-07-02 2006-01-12 Protiva Biotherapeutics, Inc. Immunostimulatory sirna molecules and uses therefor
WO2006014253A2 (en) * 2004-07-02 2006-02-09 Genentech, Inc. Factor viia variants
CA2572765C (en) * 2004-07-08 2013-05-21 Amgen Inc. Compound having improved bioefficiency when administered in a multidose regimen
EP3342782B1 (en) 2004-07-15 2022-08-17 Xencor, Inc. Optimized fc variants
WO2006006172A2 (en) * 2004-07-15 2006-01-19 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
WO2006007712A1 (en) * 2004-07-19 2006-01-26 Protiva Biotherapeutics, Inc. Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
CA2910494C (en) 2004-07-19 2018-10-23 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
EP2361931B1 (en) 2004-07-20 2017-12-06 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
CN101023182B (en) 2004-07-26 2013-04-17 健泰科生物技术公司 Methods and compositions for modulating hepatocyte growth factor activation
SG190665A1 (en) * 2004-07-30 2013-06-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
US8568637B2 (en) 2004-08-02 2013-10-29 Ramot At Tel-Aviv University Ltd. Method of forming a fiber made of peptide nanostructures
US9132116B2 (en) * 2004-08-02 2015-09-15 Willowcroft Pharm Inc. Mast cell stabilizers to prevent or treat laminitis
JP4934036B2 (en) 2004-08-17 2012-05-16 タイコ ヘルスケア グループ リミテッド パートナーシップ Anti-adhesion barrier
JP2006056807A (en) * 2004-08-18 2006-03-02 Konica Minolta Medical & Graphic Inc Preparation for use in photodynamic therapy
ATE539745T1 (en) 2004-08-19 2012-01-15 Univ Tel Aviv Future Tech Dev COMPOSITIONS FOR TREATING AMYLOID-ASSOCIATED DISEASES
JP4715133B2 (en) * 2004-08-26 2011-07-06 コニカミノルタエムジー株式会社 Anti-tumor liposome preparation and production method thereof
JP2006069929A (en) * 2004-08-31 2006-03-16 Konica Minolta Medical & Graphic Inc Preparation for treating mycosis and method for producing the same
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
WO2006027780A2 (en) * 2004-09-08 2006-03-16 Ramot At Tel Aviv University Ltd. Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same
US20080063702A1 (en) * 2004-09-09 2008-03-13 Yechezkel Barenholz Liposomal Formulations Comprising an Amphipathic Weak Base Like Tempamine for Treatment of Neurodegenerative Conditions
CN101048138B (en) * 2004-09-09 2010-12-08 耶路撒冷希伯来大学伊萨姆研发公司 Use of liposomal glucocorticoids for treating inflammatory states
EP1797127B1 (en) * 2004-09-24 2017-06-14 Amgen Inc. Modified fc molecules
US6998028B1 (en) * 2004-09-24 2006-02-14 Superpower, Inc. Methods for forming superconducting conductors
US8435948B2 (en) 2004-09-29 2013-05-07 Mount Sinai School Of Medicine Of New York University Methods for inhibiting osteoclastic bone resorption and bone loss comprising administration of an anti-FSH or anti-FSHR antibody
ATE514776T1 (en) 2004-10-05 2011-07-15 California Inst Of Techn APTAMER-REGULATED NUCLEIC ACIDS AND USES THEREOF
CA2580271A1 (en) 2004-10-05 2006-04-20 Genentech, Inc. Method for treating vasculitis
ES2671893T3 (en) * 2004-10-06 2018-06-11 Mayo Foundation For Medical Education And Research B7-H1 and PD-1 in the treatment of renal cell carcinoma
JP2008515929A (en) * 2004-10-08 2008-05-15 アルザ コーポレイション A method for inserting a lipid assembly into which a lipid linking part is preformed using microwaves
TW200612993A (en) * 2004-10-08 2006-05-01 Alza Corp Lipopolymer conjugates
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
US20090117176A1 (en) * 2004-10-26 2009-05-07 Pharma Mar, S.A. Sociedad Unipersonal Anticancer Treatments
EP1809254A2 (en) * 2004-10-28 2007-07-25 Alza Corporation Lyophilized liposome formulations and method
EP1658848B1 (en) 2004-10-29 2007-08-01 Pharma Mar S.A., Sociedad Unipersonal Formulations comprising ecteinascidin and a disaccharide
JP4990786B2 (en) 2004-11-05 2012-08-01 イネックス ファーマシューティカルズ コーポレイション Compositions and methods for stabilizing drug liposome formulations
TW200618820A (en) * 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
EP1811963A4 (en) * 2004-11-08 2010-01-06 Transave Inc Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
EP1814910A4 (en) * 2004-11-11 2009-04-29 Affymax Inc Novel peptides that bind to the erythropoietin receptor
CN101102752A (en) * 2004-11-15 2008-01-09 耶路撒冷希伯来大学伊萨姆研发公司 Combination therapy associating preferably a ceramide with acytotoxic drug
WO2006053430A1 (en) * 2004-11-17 2006-05-26 Protiva Biotherapeutics, Inc. Sirna silencing of apolipoprotein b
JP5110880B2 (en) * 2004-11-18 2012-12-26 テルモ株式会社 Pharmaceutical compositions, formulations and combination formulations
ATE544774T1 (en) * 2004-12-14 2012-02-15 Alnylam Pharmaceuticals Inc RNAI MODULATION OF MLL-AF4 AND USES THEREOF
ES2343746T3 (en) 2005-01-07 2010-08-09 Diadexus, Inc. OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE.
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
WO2006078307A1 (en) 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
WO2006080452A1 (en) * 2005-01-28 2006-08-03 Kyowa Hakko Kogyo Co., Ltd. Method for producing fine particle surface-modified with water-soluble substance
EP1853289A4 (en) 2005-01-31 2008-04-09 Vaxinnate Corp Novel polypeptide ligands for toll-like receptor 2 (tlr2)
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
EP1855694B1 (en) 2005-02-09 2020-12-02 Sarepta Therapeutics, Inc. Antisense composition for treating muscle atrophy
PT1853718E (en) 2005-02-15 2015-11-12 Univ Duke Anti-cd19 antibodies and uses in oncology
CA2598409A1 (en) * 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
EP1871807B1 (en) 2005-02-18 2012-11-28 Dana-Farber Cancer Institute, Inc. Antibodies against cxcr4 and methods of use thereof
WO2006088245A1 (en) * 2005-02-18 2006-08-24 The University Of Tokushima Polyoxyalkylene chain-containing lipid derivative and lipid film structure containing such derivative
US20060188509A1 (en) 2005-02-23 2006-08-24 Genentech, Inc. Extending time to disease progression or survival in cancer patients
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
US20060204505A1 (en) * 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
AU2006223498A1 (en) 2005-03-10 2006-09-21 Genentech, Inc. Methods and compositions for modulating vascular integrity
JP2006248978A (en) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd New liposome preparation
EP1861072A2 (en) * 2005-03-14 2007-12-05 Massachusetts Institute Of Technology Nanocells for diagnosis and treatment of diseases and disorders
US8288438B2 (en) 2005-03-21 2012-10-16 Metabolex, Inc. Methods for avoiding edema in the treatment or prevention of PPARγ-responsive diseases, including cancer
CN1840193B (en) * 2005-03-29 2010-05-12 中国科学院生物物理研究所 Nanometer capsule of anthracene nucleus anticancer antibiotic with polyethylene glycol-phospholipid
JP2008537551A (en) 2005-03-31 2008-09-18 カランド ファーマシューティカルズ， インコーポレイテッド Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
MY148086A (en) * 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
JP5047947B2 (en) 2005-05-05 2012-10-10 デューク ユニバーシティ Anti-CD19 antibody treatment for autoimmune disease
BRPI0611069A2 (en) 2005-05-06 2010-11-09 Zymogenetics Inc monoclonal antibody, humanized antibody, antibody fragment, use of an antagonist, and hybridoma
PL1899364T3 (en) 2005-05-17 2020-08-24 University Of Connecticut Compositions and methods for immunomodulation in an organism
US7919461B2 (en) * 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
EP1871163A2 (en) 2005-06-06 2008-01-02 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
WO2007005754A2 (en) * 2005-07-01 2007-01-11 Alza Corporation Liposomal delivery vehicle for hydrophobic drugs
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
KR20080039929A (en) 2005-07-22 2008-05-07 와이스 테라퓨틱스 가부시키가이샤 Anti-cd26 antibodies and methods of use thereof
WO2007016285A2 (en) * 2005-07-28 2007-02-08 Novartis Ag M-csf specific monoclonal antibody and uses thereof
JP5657862B2 (en) * 2005-07-28 2015-01-21 ノバルティス アーゲー Use of antibodies against M-CSF
US20070055199A1 (en) 2005-08-10 2007-03-08 Gilbert Scott J Drug delivery device for buccal and aural applications and other areas of the body difficult to access
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007021423A2 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
US20070054873A1 (en) * 2005-08-26 2007-03-08 Protiva Biotherapeutics, Inc. Glucocorticoid modulation of nucleic acid-mediated immune stimulation
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
EP1973928A2 (en) * 2005-10-11 2008-10-01 Ramot at Tel-Aviv University Ltd. Self-assembled fmoc-ff hydrogels
US7875602B2 (en) * 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
AR056142A1 (en) 2005-10-21 2007-09-19 Amgen Inc METHODS TO GENERATE THE MONOVALENT IGG ANTIBODY
PL1978993T3 (en) 2005-10-31 2017-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating cancer based on human fzd receptors
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
JP2009513716A (en) 2005-11-01 2009-04-02 アルナイラム ファーマシューティカルズ インコーポレイテッド Inhibition of influenza virus replication by RNAi
EP1948674A4 (en) 2005-11-02 2009-02-04 Protiva Biotherapeutics Inc Modified sirna molecules and uses thereof
US7879212B2 (en) * 2005-11-03 2011-02-01 Ramot At Tel-Aviv University Ltd. Peptide nanostructure-coated electrodes
DE102005053066A1 (en) 2005-11-04 2007-05-10 Basf Ag Use of copolymers as solubilizers for sparingly water-soluble compounds
WO2007056264A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007056236A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
US20070190180A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
DK2564864T3 (en) 2005-11-12 2015-04-07 Trustees Of The Leland Board Of FGF-2 related methods for the diagnosis and treatment of depression
LT2380592T (en) 2005-11-14 2018-05-10 Teva Pharmaceuticals International Gmbh Antagonist antibody directed against calcitonin gene-related peptide
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
SI1948798T1 (en) 2005-11-18 2015-09-30 Glenmark Pharmaceuticals S.A. Anti-alpha2 integrin antibodies and their uses
EP1966377A2 (en) 2005-11-21 2008-09-10 Isis Pharmaceuticals, Inc. Modulation of eif4e-bp2 expression
JP2009516514A (en) 2005-11-21 2009-04-23 ジェネンテック・インコーポレーテッド Novel gene disruptions, compositions and methods related thereto
WO2007064658A2 (en) * 2005-11-30 2007-06-07 Transave, Inc. Safe and effective methods of administering therapeutic agents
WO2007065027A2 (en) 2005-12-02 2007-06-07 Dana Farber Cancer Institute Carbonic anhydrase ix (g250) antibodies and methods of use thereof
ES2547689T3 (en) 2005-12-02 2015-10-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling that involve antibodies that bind to IL-22 and IL-22R
WO2007066335A2 (en) * 2005-12-08 2007-06-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods for affecting liposome composition by ultrasound irradiation
JP2009523119A (en) * 2005-12-09 2009-06-18 ビーエーエスエフ ソシエタス・ヨーロピア Use of polyvinyl lactam-polyoxyalkylene block copolymers as solubilizers for compounds that are poorly soluble in water
WO2007070705A2 (en) 2005-12-15 2007-06-21 The Trustees Of The University Of Pennsylvania Cationic lipid-mediated vectors
US20090215084A1 (en) * 2006-01-05 2009-08-27 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
BRPI0706314A2 (en) 2006-01-05 2011-03-22 Novartis Ag E Xoma Technology Ltd method of treating a patient suffering from an osteolytic disorder
US20100015642A1 (en) * 2006-01-05 2010-01-21 Kwon Eugene D B7-h1 and survivin in cancer
US7951934B2 (en) 2006-01-26 2011-05-31 Isis Pharmaceuticals, Inc. Compositions and their uses directed to huntingtin
ES2502966T3 (en) 2006-01-26 2014-10-06 Recopharma Ab Compositions and methods to inhibit viral adhesion
US7829097B2 (en) * 2006-02-06 2010-11-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of HMGB1 for protection against ischemia reperfusion injury
CA2638821A1 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
US8389688B2 (en) 2006-03-06 2013-03-05 Aeres Biomedical, Ltd. Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US20070218116A1 (en) * 2006-03-14 2007-09-20 Schwendener Reto A Compositions and methods for the treatment of tumors and tumor metastases
US9119782B2 (en) 2006-03-20 2015-09-01 Mary P. McCourt Drug delivery means
RS54156B1 (en) 2006-03-21 2015-12-31 Genentech Inc. Combinatorial therapy involving alpha5beta1 antagonists
EP2389951A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
CA2873833A1 (en) 2006-03-31 2007-10-11 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of eg5 gene
EP2614839A3 (en) 2006-04-05 2015-01-28 Genentech, Inc. Method for using BOC/CDO to modulate hedgehog signaling
US8758723B2 (en) 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
EP2010662A2 (en) 2006-04-19 2009-01-07 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
WO2007124361A2 (en) * 2006-04-20 2007-11-01 Mayo Foundation For Medical Education And Research Soluble b7-h1
CA2648481C (en) 2006-04-21 2017-03-07 Melinda Jane Frost Pestivirus species
CA2656990A1 (en) * 2006-04-28 2007-11-08 University Of South Florida Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
WO2007127428A2 (en) * 2006-04-28 2007-11-08 University Of Florida Research Foundation, Inc. Double-stranded/self-complementary vectors with a truncated cba promoter and methods of gene delivery
JP4812874B2 (en) 2006-04-28 2011-11-09 アルナイラム ファーマシューティカルズ， インコーポレイテッド Composition and method for suppressing expression of JC virus gene
WO2008018932A2 (en) * 2006-05-01 2008-02-14 The Board Of Trustees Of The Leland Stanford Junior University Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury
WO2007125173A2 (en) * 2006-05-03 2007-11-08 Baltic Technology Development, Ltd. Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
US20070264322A1 (en) * 2006-05-10 2007-11-15 Huang Ken S Method for making liposomes conjugated with temperature-sensitive ligands
US20080014205A1 (en) 2006-05-15 2008-01-17 Lawrence Horowitz Neutralizing Antibodies to Influenza Viruses
EP2023813A4 (en) * 2006-05-15 2013-03-13 Dmitri B Kirpotin Magnetic microparticles comprising organic substances
US7812150B2 (en) 2006-05-19 2010-10-12 Alnylam Pharmaceuticals, Inc. RNAi modulation of Aha and therapeutic uses thereof
EP2029157A4 (en) * 2006-05-19 2009-11-18 Georgia Tech Res Inst Abc transporter ligand
US7888498B2 (en) * 2006-05-22 2011-02-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of IKK-B gene
WO2007137301A2 (en) * 2006-05-23 2007-11-29 Isis Pharmaceuticals, Inc. Modulation of chrebp expression
US8598333B2 (en) * 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
US7915399B2 (en) * 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
WO2007149433A2 (en) 2006-06-19 2007-12-27 The Johns Hopkins University Tumor-specific delivery of therapeutic agents via liposomase
AU2007281876B2 (en) 2006-06-26 2013-09-05 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
EP2037928B1 (en) 2006-06-26 2012-01-11 Amgen Inc. Methods for treating atherosclerosis
JP5072275B2 (en) * 2006-07-03 2012-11-14 テルモ株式会社 Method for separating closed vesicles, method for producing preparation and evaluation method
WO2008054561A2 (en) 2006-07-11 2008-05-08 University Of Medicine And Dentistry Of New Jersey Proteins, nucleic acids encoding the same and associated methods of use
EP2049138A4 (en) * 2006-07-14 2011-11-09 Georgia Tech Res Inst Clc channel ligand
US8343539B2 (en) 2006-07-14 2013-01-01 Regents Of The University Of Minnesota Compounds that bind α5β1 integrin and methods of use
EP2046809B1 (en) 2006-07-19 2016-12-07 The Trustees Of The University Of Pennsylvania Wsx-1/il-27 as a target for anti-inflammatory responses
US8198253B2 (en) 2006-07-19 2012-06-12 Isis Pharmaceuticals, Inc. Compositions and their uses directed to HBXIP
JP4936312B2 (en) * 2006-07-20 2012-05-23 株式会社島津製作所 Novel amphiphile, drug delivery system and molecular imaging system using the same
WO2008013918A2 (en) * 2006-07-26 2008-01-31 Myelin Repair Foundation, Inc. Cell cycle regulation and differentiation
JP5406027B2 (en) 2006-08-04 2014-02-05 ノバルティス アーゲー EphB3-specific antibodies and uses thereof
US8586006B2 (en) 2006-08-09 2013-11-19 Institute For Systems Biology Organ-specific proteins and methods of their use
AU2007285976B2 (en) 2006-08-14 2011-08-18 Xencor, Inc Optimized antibodies that target CD19
KR101433544B1 (en) 2006-08-18 2014-08-27 노바르티스 아게 Prlr-specific antibody and uses thereof
EP2423332A1 (en) 2006-08-25 2012-02-29 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
DK2484696T3 (en) 2006-08-28 2017-10-02 Kyowa Hakko Kirin Co Ltd Antagonistic hLIGHT-specific human monoclonal antibodies
TWI439282B (en) 2006-08-29 2014-06-01 Genentech Inc Method of treating stroke with thrombolytic agent
US8466262B2 (en) 2006-09-01 2013-06-18 Zymogenetics, Inc. Variable region sequences of IL-31 monoclonal antibodies and methods of use
CA2600220C (en) * 2006-09-07 2014-12-09 Canadian Blood Services Surface cross-linked lipidic particles, methods of production and uses therefor
BRPI0717431A2 (en) * 2006-09-29 2013-11-12 Oncomed Pharm Inc CANCER DIAGNOSTIC AND TREATMENT COMPOSITIONS AND METHODS
CN101557818A (en) 2006-10-03 2009-10-14 新泽西医科和牙科大学 ATAP peptides, nucleic acids encoding the same and associated methods of use
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US7820623B2 (en) 2006-10-25 2010-10-26 Amgen Inc. Conjugated toxin peptide therapeutic agents
PL2087002T3 (en) 2006-10-27 2015-02-27 Lpath Inc Compositions and methods for binding sphingosine-1-phosphate
CN101687031B (en) 2006-10-27 2014-05-14 勒帕斯公司 Compositions and methods for treating ocular diseases and conditions
US8158595B2 (en) 2006-11-09 2012-04-17 California Institute Of Technology Modular aptamer-regulated ribozymes
DK2080012T3 (en) * 2006-11-10 2013-06-17 Dimerix Bioscience Pty Ltd Methods for analyzing test compounds at associated receptors.
CA2669399A1 (en) 2006-11-13 2008-05-29 Eli Lilly & Co. Thienopyrimidinones for treatment of inflammatory disorders and cancers
EP2104513B1 (en) 2006-11-27 2015-05-20 diaDexus, Inc. Ovr110 antibody compositions and methods of use
EA200900767A1 (en) 2006-12-07 2009-12-30 Новартис Аг ANTAGONISTIC ANTIBODIES AGAINST EPHB3
EP1932517A3 (en) * 2006-12-11 2008-07-16 Universiteit Utrecht Holding B.V. Liposomes containing a polyphenol derivative such as caffeic acid and a method of post-loading thereof
EP2114413B1 (en) * 2006-12-18 2014-10-22 The Johns Hopkins University Therapeutics for treating cancer using 3-bromopyruvate
US8834920B2 (en) 2006-12-21 2014-09-16 Alza Corporation Liposome composition for targeting egfr receptor
WO2008079973A2 (en) * 2006-12-21 2008-07-03 Centocor, Inc. Egfr binding peptides and uses thereof
US8278415B2 (en) 2006-12-21 2012-10-02 Centocor, Inc. Dimeric high affinity EGFR constructs and uses thereof
EP2913341A1 (en) 2006-12-22 2015-09-02 University of Utah Research Foundation Method of detecting ocular diseases and pathologic conditions and treatment of same
US8440185B2 (en) * 2006-12-26 2013-05-14 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
US20090142342A1 (en) * 2006-12-27 2009-06-04 Johns Hopkins University B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases
AU2007339762B2 (en) * 2006-12-27 2011-03-31 The Johns Hopkins University Compositions and methods for treating inflammation and auto-immune diseases
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US8048998B2 (en) * 2007-01-19 2011-11-01 Exiqon A/S Mediated cellular delivery of LNA oligonucleotides
US20100329664A1 (en) * 2007-01-23 2010-12-30 Lim Dae-Soon Shutter device for camera
US20100093836A1 (en) 2007-01-29 2010-04-15 Isis Pharmaceuticals, Inc Compounds and methods for modulating protein expression
WO2008094275A1 (en) 2007-01-30 2008-08-07 New York University Peptides for treatment of conditions associated with nitric oxide
CN101663407B (en) 2007-02-22 2017-08-08 健泰科生物技术公司 method for detecting inflammatory bowel disease
PE20090681A1 (en) 2007-03-02 2009-06-10 Genentech Inc PREDICTION OF RESPONSE TO A HER INHIBITOR
AU2008227852B2 (en) * 2007-03-19 2011-02-24 Fresenius Kabi Oncology Ltd. Proliposomal and liposomal compositions
JP4510842B2 (en) * 2007-03-26 2010-07-28 キヤノン株式会社 Polyhydroxyalkanoate-coated liposome
AP3018A (en) 2007-03-29 2014-10-31 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expressionof a gene from the ebola
EP2164868B1 (en) 2007-05-04 2015-03-25 Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA Engineered rabbit antibody variable domains and uses thereof
EP2737907A3 (en) 2007-05-07 2014-11-05 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2008141278A1 (en) * 2007-05-11 2008-11-20 Centocor, Inc. Method for preparing antibody conjugates
US20090175784A1 (en) 2007-05-11 2009-07-09 Joshua Goldstein Anti-Alpha V Immunoliposome Composition, Methods, and Uses
US20090196913A1 (en) * 2007-05-11 2009-08-06 Ken Shi Kun Huang Anti-Alpha-V Immunoliposome Composition, Methods, and Uses
EP2160200B1 (en) 2007-05-14 2013-07-10 The University of Chicago Antibody-LIGHT fusion products as cancer therapeutics
EP2173381B1 (en) 2007-05-14 2013-10-02 NovImmune SA Fc receptor-binding polypeptides with modified effector functions
EP2162540A2 (en) * 2007-05-22 2010-03-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
WO2008148023A2 (en) * 2007-05-23 2008-12-04 Medical College Of Georgia Research Institute, Inc. Compositions and methods for treating neurological disorders
JP2010527618A (en) 2007-05-24 2010-08-19 アメリカ合衆国 Nuclear protein transmission through the nucleoside salvage pathway
AU2008260135A1 (en) 2007-05-30 2008-12-11 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
AR066984A1 (en) 2007-06-15 2009-09-23 Novartis Ag INHIBITION OF THE EXPRESSION OF THE ALFA SUBUNITY OF THE SODIUM EPITELIAL CHANNEL (ENAC) THROUGH ARNI (INTERFERENCE RNA)
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
WO2009029342A2 (en) * 2007-07-13 2009-03-05 The Johns Hopkins University B7-dc variants
US20090082217A1 (en) * 2007-07-16 2009-03-26 California Institute Of Technology Selection of nucleic acid-based sensor domains within nucleic acid switch platform
DK2474557T3 (en) 2007-07-16 2014-11-10 Genentech Inc Anti-CD79b antibodies and immune conjugates and methods of use
ES2528922T3 (en) 2007-07-16 2015-02-13 Genentech, Inc. Humanized and immunoconjugate anti-CD79b antibodies and methods of use
CA2693169C (en) * 2007-07-19 2016-01-12 Metabolex, Inc. N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
EP2489730B1 (en) 2007-07-26 2015-12-30 Amgen, Inc Modified lecithin-cholesterol acyltransferase enzymes
EP2173781A1 (en) * 2007-07-26 2010-04-14 Basf Se Process for preparing copolymers obtained by graft polymerization in solution and based on polyethers in solid form
US7666973B2 (en) 2007-07-30 2010-02-23 Tyco Healthcare Group Lp Carbonate copolymers
HUE025283T2 (en) 2007-08-02 2016-03-29 Gilead Biologics Inc Lox and l0xl2 inhibitors and uses thereof
KR20100046185A (en) * 2007-08-09 2010-05-06 다이이찌 산쿄 가부시키가이샤 Immunoliposome inducing apoptosis into cell expressing death domain-containing receptor
US8268958B2 (en) 2007-08-15 2012-09-18 Tyco Healthcare Group Ip Phospholipid copolymers
US20090048423A1 (en) * 2007-08-15 2009-02-19 Tyco Healthcare Group Lp Phospholipid Copolymers
US8367815B2 (en) * 2007-08-28 2013-02-05 California Institute Of Technology Modular polynucleotides for ligand-controlled regulatory systems
US20120165387A1 (en) 2007-08-28 2012-06-28 Smolke Christina D General composition framework for ligand-controlled RNA regulatory systems
AU2008296012A1 (en) * 2007-09-07 2009-03-12 Gencia Corporation Mitochondrial compositions and uses thereof
US8865667B2 (en) * 2007-09-12 2014-10-21 California Institute Of Technology Higher-order cellular information processing devices
CN102203002A (en) * 2007-09-21 2011-09-28 细胞免疫科学公司 Nanotherapeutic colloidal metal compositions and methods
US20110014118A1 (en) * 2007-09-21 2011-01-20 Lawrence Tamarkin Nanotherapeutic colloidal metal compositions and methods
WO2009039628A1 (en) 2007-09-27 2009-04-02 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
JP2010540498A (en) 2007-09-28 2010-12-24 ウニヴェルズィテーツシュピタール バーゼル Immunoliposomes for the treatment of cancer
MX2010003465A (en) 2007-10-02 2010-07-05 Amgen Inc Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof.
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
ES2664822T3 (en) * 2007-10-16 2018-04-23 Biocon Limited A solid pharmaceutical composition orally administrable and a process thereof
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
US20110152346A1 (en) * 2007-11-05 2011-06-23 Baltic Technology Development Ltd. Use of Oligonucleotides with Modified Bases in Hybridization of Nucleic Acids
EP2219452B1 (en) 2007-11-05 2015-10-14 MedImmune, LLC Methods of treating scleroderma
EP3360567A1 (en) 2007-11-07 2018-08-15 Genentech, Inc. Amp for use in treating microbial disorders
EP2220116B1 (en) * 2007-11-12 2012-09-05 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
US20110033476A1 (en) * 2007-11-12 2011-02-10 Theraclone Sciences Inc. Compositions and methods for the therapy and diagnosis of influenza
US8598165B2 (en) 2007-11-26 2013-12-03 University Of Kansas Morpholines as selective inhibitors of cytochrome P450 2A13
EP3524619A1 (en) 2007-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
HUE036548T2 (en) 2007-12-07 2018-08-28 Zymogenetics Inc Humanized antibody molecules specific for IL-31
US9029524B2 (en) * 2007-12-10 2015-05-12 California Institute Of Technology Signal activated RNA interference
US7871985B2 (en) 2007-12-10 2011-01-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor VII gene
EP3587450A1 (en) 2007-12-17 2020-01-01 Pfizer Limited Treatment of interstitial cystitis with ngf inhibitors
US8962806B2 (en) 2007-12-28 2015-02-24 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
EP3100718B1 (en) 2008-01-02 2019-11-27 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
US20090181094A1 (en) * 2008-01-15 2009-07-16 Eric Yueh-Lang Sheu Molecular Cage for Sustained Release Control of Pharmaceutical and Cosmetic Agents
AR070141A1 (en) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa SPECIFIC HUMANIZED ANTIBODIES FOR VON WILLEBRAND FACTOR
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
AU2009210636B2 (en) 2008-01-31 2014-08-28 Genentech, Inc. Anti-CD79b antibodies and immunoconjugates and methods of use
US20110020325A1 (en) * 2008-02-29 2011-01-27 Kwon Eugene D Methods for reducing granulomatous inflammation
CN102014932B (en) * 2008-03-05 2015-11-25 阿尔尼拉姆医药品有限公司 For suppressing compositions and the method for Eg5 and VEGF gene expression
MX2010009885A (en) 2008-03-10 2010-11-30 Theraclone Sciences Inc Compositions and methods for the therapy and diagnosis of cytomegalovirus infections.
EP2105145A1 (en) * 2008-03-27 2009-09-30 ETH Zürich Method for muscle-specific delivery lipid-conjugated oligonucleotides
AU2009228058A1 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
PL2280704T3 (en) * 2008-03-31 2015-10-30 Cymabay Therapeutics Inc Oxymethylene aryl compounds and uses thereof
JP2011516065A (en) 2008-04-04 2011-05-26 カランド ファーマシューティカルズ， インコーポレイテッド Compositions and uses of EPAS1 inhibitors
PL2279412T3 (en) 2008-04-09 2017-12-29 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
WO2009126306A2 (en) 2008-04-10 2009-10-15 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
DK2279254T3 (en) 2008-04-15 2017-09-18 Protiva Biotherapeutics Inc PRESENT UNKNOWN LIPID FORMS FOR NUCLEIC ACID ADMINISTRATION
US8324366B2 (en) 2008-04-29 2012-12-04 Alnylam Pharmaceuticals, Inc. Compositions and methods for delivering RNAI using lipoproteins
EP2280995A2 (en) * 2008-04-29 2011-02-09 Wyeth LLC Methods for treating inflammation
JP2011519912A (en) * 2008-05-09 2011-07-14 リコファーマ アーベー Compositions and methods for inhibiting Shiga toxin and Shiga-like toxin
WO2009136297A2 (en) * 2008-05-09 2009-11-12 Recopharma Ab Compositions and methods for inhibiting toxin a from clostridium difficile
PL2279004T3 (en) 2008-05-16 2015-06-30 Hoffmann La Roche Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists
US8093018B2 (en) 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
CN105363034A (en) * 2008-05-23 2016-03-02 香港大学 Combination therapy for the treatment of influenza
US20110070298A1 (en) 2008-06-05 2011-03-24 Immunovaccine Technologies Inc. Compositions Comprising Liposomes, An Antigen, A Polynucleotide and A Carrier Comprising a Continuous Phase of a Hydrophobic Substance
US20110104056A1 (en) 2008-06-05 2011-05-05 Isao Hara Novel molecular assembly, molecular probe for molecular imaging and molecular probe for drug delivery system using the same, and molecular imaging system and drug delivery system
US8173621B2 (en) * 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
WO2009155431A1 (en) * 2008-06-18 2009-12-23 University Of Louisville Research Foundation, Inc. Methods for targeted cancer treatment and detection
US20100003315A1 (en) 2008-07-02 2010-01-07 Willeford Kenneth L Method and Composition for the Treatment of Skin Conditions
ME02069B (en) 2008-07-08 2015-05-20 Oncomed Pharm Inc Notch1 receptor binding agents and methods of use thereof
EP2310440A4 (en) * 2008-07-10 2013-06-05 Serina Therapeutics Inc Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds
US20100008900A1 (en) * 2008-07-14 2010-01-14 The University Of Hong Kong Annexin ii compositions for treating or monitoring inflammation or immune-mediated disorders
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
US20110237646A1 (en) * 2008-08-07 2011-09-29 Isis Pharmaceuticals, Inc. Modulation of transthyretin expression for the treatment of cns related disorders
WO2010019702A2 (en) 2008-08-12 2010-02-18 Oncomed Pharmaceuticals, Inc. Ddr1-binding agents and methods of use thereof
CN102186820B (en) 2008-08-15 2013-08-28 乔治城大学 Fluorescent regulators of rassf1a expression and human cancer cell proliferation
PL2331092T3 (en) * 2008-08-21 2014-08-29 Univ Johns Hopkins Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer
CN103508936A (en) * 2008-08-22 2014-01-15 赛诺菲-安万特 Intermediate for preparation of indole benzylamine compound
NZ591130A (en) 2008-08-25 2012-09-28 Amplimmune Inc Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
WO2010027818A2 (en) 2008-08-25 2010-03-11 Dana-Farber Cancer Institute, Inc. Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
EP3081648A1 (en) 2008-08-25 2016-10-19 Excaliard Pharmaceuticals, Inc. Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
EP2328919A2 (en) * 2008-08-25 2011-06-08 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
EP2331690B1 (en) 2008-09-02 2016-01-13 Alnylam Pharmaceuticals Inc. Compositions and methods for inhibiting expression of mutant egfr gene
AU2009291747B2 (en) 2008-09-10 2016-05-26 Genentech, Inc. Methods for inhibiting ocular angiogenesis
TWI516501B (en) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Pcsk9 antagonists
TW201014605A (en) * 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
US10138485B2 (en) 2008-09-22 2018-11-27 Rxi Pharmaceuticals Corporation Neutral nanotransporters
EP2334793B1 (en) 2008-09-25 2016-04-06 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of serum amyloid a gene
ES2475065T3 (en) 2008-10-09 2014-07-10 Tekmira Pharmaceuticals Corporation Enhanced amino acids and methods for nucleic acid administration
US9173840B2 (en) 2008-10-09 2015-11-03 Northeastern University Multifunctional self-assembling polymeric nanosystems
NZ592867A (en) 2008-10-20 2013-05-31 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of transthyretin
KR20110082145A (en) 2008-10-21 2011-07-18 메타볼렉스, 인코포레이티드 Aryl gpr120 receptor agonists and uses thereof
JP5382380B2 (en) * 2008-10-21 2014-01-08 インターナショナル ワクチン インスティテュート Novel Shigella protein antigen and method
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
MX2011004696A (en) * 2008-11-06 2011-10-14 Glenmark Pharmaceuticals Sa Treatment with anti-alpha2 integrin antibodies.
KR101967417B1 (en) 2008-11-10 2019-04-10 알닐람 파마슈티칼스 인코포레이티드 Novel lipids and compositions for the delivery of therapeutics
ES2674719T3 (en) 2008-11-13 2018-07-03 Gilead Calistoga Llc Therapies for hematologic malignancies
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CA2744158A1 (en) 2008-11-22 2010-05-27 Genentech, Inc. Anti-angiogenesis therapy for the treatment of breast cancer
US20110230399A1 (en) * 2008-11-25 2011-09-22 Bowen Richard L Methods for Treating Obesity Related Disease
US20110160222A1 (en) * 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
CA2745811C (en) 2008-12-04 2021-07-13 Joseph Collard Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
KR101749352B1 (en) 2008-12-04 2017-06-20 큐알엔에이, 인크. Treatment of sirtuin 1(sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
CN102317458B (en) 2008-12-04 2018-01-02 库尔纳公司 Pass through treatment of the suppression of erythropoietin(EPO) (EPO) natural antisense transcript to EPO relevant diseases
EP3225281A1 (en) 2008-12-10 2017-10-04 Alnylam Pharmaceuticals, Inc. Gnaq targeted dsrna compositions and methods for inhibiting expression
WO2010068680A1 (en) 2008-12-10 2010-06-17 Mount Sinai School Of Medicine Of New York University Thelper cell type 17 lineage-specific adjuvants, compositions and methods
AR074760A1 (en) * 2008-12-18 2011-02-09 Metabolex Inc GPR120 RECEIVER AGONISTS AND USES OF THE SAME IN MEDICINES FOR THE TREATMENT OF DIABETES AND METABOLIC SYNDROME.
AR074776A1 (en) 2008-12-18 2011-02-09 Sanofi Aventis METHOD TO TREAT MACULAR DEGENERATION; MODULATING THE PATIENT'S IMMUNE SYSTEM
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
MY171292A (en) * 2008-12-22 2019-10-07 Creabilis S A Synthesis of polymer conjugates of indolocarbazole compounds
NZ593649A (en) * 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
CA2748057C (en) 2008-12-23 2018-07-03 Pharmasset, Inc. Nucleoside phosphoramidates
WO2010078536A1 (en) 2009-01-05 2010-07-08 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
AU2010208035B2 (en) 2009-01-29 2016-06-23 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
KR101805199B1 (en) 2009-02-12 2017-12-05 큐알엔에이, 인크. Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
EP3009150B1 (en) 2009-02-12 2019-11-13 CuRNA, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
US8329882B2 (en) 2009-02-18 2012-12-11 California Institute Of Technology Genetic control of mammalian cells with synthetic RNA regulatory systems
US20120041051A1 (en) 2009-02-26 2012-02-16 Kevin Fitzgerald Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
EP3424939A1 (en) 2009-03-02 2019-01-09 Alnylam Pharmaceuticals Inc. Nucleic acid chemical modifications
US20110319317A1 (en) 2009-03-04 2011-12-29 Opko Curna, Llc Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt1
AU2010223967B2 (en) 2009-03-12 2015-07-30 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
EP2228059A1 (en) 2009-03-12 2010-09-15 Universitätsspital Basel Chemotherapeutic composition for the treatment of cancer
WO2010107733A2 (en) 2009-03-16 2010-09-23 Curna, Inc. Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
SI3260136T1 (en) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv) -neutralizing antibodies
EP2408920B1 (en) 2009-03-17 2017-03-08 CuRNA, Inc. Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
US8440677B2 (en) 2009-03-24 2013-05-14 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
CN103755808B (en) 2009-03-25 2016-02-10 霍夫曼-拉罗奇有限公司 Anti-alpha 5 beta 1 antibodies and application thereof
WO2010120561A1 (en) 2009-04-01 2010-10-21 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates and methods of use
EP2413967A1 (en) 2009-04-01 2012-02-08 F. Hoffmann-La Roche AG Treatment of insulin-resistant disorders
US9145555B2 (en) 2009-04-02 2015-09-29 California Institute Of Technology Integrated—ligand-responsive microRNAs
JP2012524126A (en) * 2009-04-20 2012-10-11 ギリアド カリストガ リミテッド ライアビリティ カンパニー Method for treating solid tumors
EP3248618A1 (en) 2009-04-22 2017-11-29 Massachusetts Institute Of Technology Innate immune suppression enables repeated delivery of long rna molecules
CA2759506A1 (en) 2009-04-23 2010-10-28 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
CN102459346B (en) 2009-04-27 2016-10-26 昂考梅德药品有限公司 The method manufacturing heteromultimers molecule
EP2248903A1 (en) 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages
US8524784B2 (en) 2009-04-30 2013-09-03 Intezyne Technologies, Incorporated Polymer micelles containing anthracylines for the treatment of cancer
US8524783B2 (en) 2009-04-30 2013-09-03 Intezyne Technologies, Incorporated Polymer micelles containing anthracylines for the treatment of cancer
ES2661787T3 (en) 2009-05-01 2018-04-04 Curna, Inc. Treatment of hemoglobin-related diseases (hbf / hbg) by inhibition of natural antisense transcript for hbf / hbg
CA3045126A1 (en) 2009-05-05 2010-11-11 Arbutus Biopharma Corporation Methods of delivering oligonucleotides to immune cells
NZ596186A (en) 2009-05-05 2014-03-28 Alnylam Pharmaceuticals Inc Lipid compositions
WO2010128407A2 (en) 2009-05-05 2010-11-11 Novimmune S.A. Anti-il-17f antibodies and methods of use thereof
CN103223177B (en) 2009-05-06 2016-08-10 库尔纳公司 By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene
KR101722541B1 (en) 2009-05-06 2017-04-04 큐알엔에이, 인크. Treatment of tristetraproline(ttp) related diseases by inhibition of natural antisense transcript to ttp
CN102575251B (en) 2009-05-18 2018-12-04 库尔纳公司 The relevant disease of the reprogramming factor is treated by inhibiting the natural antisense transcript for the reprogramming factor
EP2432499A2 (en) 2009-05-20 2012-03-28 Schering Corporation Modulation of pilr receptors to treat microbial infections
AU2010249787A1 (en) 2009-05-20 2011-12-22 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
TWI583692B (en) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
KR101703695B1 (en) 2009-05-22 2017-02-08 큐알엔에이, 인크. Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
EP2435571B1 (en) 2009-05-28 2016-12-14 CuRNA, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
KR101766408B1 (en) 2009-06-10 2017-08-10 알닐람 파마슈티칼스 인코포레이티드 Improved lipid formulation
WO2010143193A1 (en) 2009-06-11 2010-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Targeted liposomes comprising n-containing bisphosphonates and uses thereof
EP2443238B1 (en) 2009-06-16 2017-03-22 CuRNA, Inc. Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
JP5944311B2 (en) 2009-06-16 2016-07-05 クルナ・インコーポレーテッド Treatment of collagen gene-related diseases by suppression of natural antisense transcripts against collagen genes
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
CN102597238B (en) 2009-06-24 2016-06-29 库尔纳公司 The relevant disease of TNFR2 is treated by suppressing for the natural antisense transcript of tumor necrosis factor receptor 2 (TNFR2)
WO2010151674A2 (en) 2009-06-26 2010-12-29 Curna, Inc. Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
WO2010151808A1 (en) 2009-06-26 2010-12-29 Sea Lane Biotechnologies, Llc Expression of surrogate light chains
WO2011000384A1 (en) 2009-06-30 2011-01-06 Общество С Ограниченной Ответсвенностью "Онкомакс" Method for suppressing tumor growth by blocking fibroblast growth factor receptor, and method for diagnosing malignant neoplasms
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
JP5766188B2 (en) 2009-07-01 2015-08-19 プロチバ バイオセラピューティクス インコーポレイティッド Lipid formulations for delivering therapeutic agents to solid tumors
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
WO2011005715A1 (en) 2009-07-07 2011-01-13 Genentech, Inc. Diagnosis and treatment of autoimmune demyelinating diseases
US8920775B2 (en) 2009-07-17 2014-12-30 Technical University Of Denmark Loading technique for preparing radionuclide containing nanoparticles
KR20120049281A (en) 2009-07-21 2012-05-16 길리아드 칼리스토가 엘엘씨 Treatment of liver disorders with pi3k inhibitors
WO2011017297A2 (en) 2009-08-03 2011-02-10 The University Of North Carolina At Chapel Hill Biodegradable delivery system complexes for the delivery of bioactive compounds
JP6128848B2 (en) 2009-08-05 2017-05-17 クルナ・インコーポレーテッド Treatment of insulin gene (INS) -related diseases by suppression of natural antisense transcripts against the insulin gene (INS)
EP2464336A4 (en) 2009-08-14 2013-11-20 Alnylam Pharmaceuticals Inc Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
SG178419A1 (en) 2009-08-15 2012-04-27 Genentech Inc Anti-angiogenesis therapy for the treatment of previously treated breast cancer
FR2955324A1 (en) 2010-01-15 2011-07-22 Sanofi Aventis DISUBSTITUTED 4- (5-AMINOMETHYL-PHENYL) -PIPERIDIN-1-YL] -1H-INDOL-3-YL] -METHANONES
WO2011031482A2 (en) 2009-08-25 2011-03-17 Curna, Inc. Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
WO2011026132A2 (en) 2009-08-31 2011-03-03 1/3Acamplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
US20110059111A1 (en) 2009-09-01 2011-03-10 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
CA2772715C (en) 2009-09-02 2019-03-26 Genentech, Inc. Mutant smoothened and methods of using the same
JP5909185B2 (en) 2009-10-01 2016-04-26 シマベイ セラピューティクス， インコーポレーテッド Substituted tetrazol-1-ylphenoxymethylthiazol-2-ylpiperidinylpyrimidine salt
EP2488210A4 (en) 2009-10-12 2014-04-30 Smith Holdings Llc Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
WO2011047267A1 (en) * 2009-10-15 2011-04-21 Genentech, Inc. Chimeric fibroblast growth factors with altered receptor specificity
EP2488204B1 (en) 2009-10-16 2016-04-06 Oncomed Pharmaceuticals, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
CN102711826B (en) 2009-10-22 2017-03-29 霍夫曼-拉罗奇有限公司 For the method and composition that the HEPSIN for regulating and controlling macrophage-stimulating albumen is activated
WO2011053468A1 (en) 2009-10-30 2011-05-05 Sanofi-Aventis Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders
ES2651682T3 (en) 2009-11-05 2018-01-29 Rhizen Pharmaceuticals S.A. Novelty kinase modulators
WO2011056234A1 (en) 2009-11-06 2011-05-12 Fibrogen, Inc. Treatment for radiation-induced disorders
US9260517B2 (en) 2009-11-17 2016-02-16 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
CA2781887C (en) 2009-11-30 2018-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2509997B1 (en) 2009-12-07 2017-08-30 i2 Pharmaceuticals, Inc. Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
CA3044884A1 (en) 2009-12-07 2011-06-16 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
US8901129B2 (en) 2009-12-11 2014-12-02 Genecode As Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators
US20130004490A1 (en) 2009-12-14 2013-01-03 The United States of America, as represented by the Secretary, Department Delivery of transthyretin across the blood-brain barrier as a treatment for alzheimer's disease
WO2011084455A2 (en) 2009-12-16 2011-07-14 Opko Curna, Llc. Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
US8691227B2 (en) 2009-12-17 2014-04-08 Merck Sharp & Dohme Corp. Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
ES2749426T3 (en) 2009-12-18 2020-03-20 Univ British Columbia Nucleic Acid Administration Methods and Compositions
RU2012131280A (en) 2009-12-23 2014-02-10 Санофи [4- (5-AMINOMETHYL-2-fluorophenyl) piperidin-1-yl] - (1H-pyrrolopyridinyl) methanones and their synthesis
JP5944831B2 (en) 2009-12-23 2016-07-05 シュニムネ ゲーエムベーハーＳＹＮＩＭＭＵＮＥ ＧｍｂＨ Anti-FLT3 antibody and method of use thereof
CN102791702A (en) 2009-12-23 2012-11-21 赛诺菲 Prodrugs of [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1H-pyrrolo-pyridin-yl)-methanones and synthesis thereof
CN102869776B (en) 2009-12-23 2017-06-23 库尔纳公司 HGF relevant diseases are treated by suppressing the natural antisense transcript of HGF (HGF)
KR101793753B1 (en) 2009-12-23 2017-11-03 큐알엔에이, 인크. Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
WO2011080796A1 (en) 2009-12-28 2011-07-07 Oncotherapy Science, Inc. Anti-cdh3 antibodies and uses thereof
EP2519633B1 (en) 2009-12-29 2017-10-25 CuRNA, Inc. Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
WO2011090741A2 (en) 2009-12-29 2011-07-28 Opko Curna, Llc TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
US20110159588A1 (en) 2009-12-30 2011-06-30 Kui Lin Methods for Modulating a PDGF-AA Mediated Biological Response
NO2521784T3 (en) 2010-01-04 2018-05-05
US8912157B2 (en) 2010-01-06 2014-12-16 Curna, Inc. Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
JPWO2011083845A1 (en) * 2010-01-08 2013-05-16 富士フイルム株式会社 Targeting agent for tumor site
DK2524039T3 (en) 2010-01-11 2018-03-12 Curna Inc TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG
TWI535445B (en) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt antagonists and methods of treatment and screening
MX2012008085A (en) 2010-01-13 2012-09-12 Oncomed Pharm Inc Notch1 binding agents and methods of use thereof.
EP2525808A2 (en) 2010-01-19 2012-11-28 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for male reproductive disorders
WO2011089211A1 (en) 2010-01-22 2011-07-28 Synimmune Gmbh Anti-cd133 antibodies and methods of using the same
WO2011091390A2 (en) 2010-01-25 2011-07-28 Opko Curna, Llc Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
US8198337B2 (en) * 2010-01-27 2012-06-12 Momentive Performance Materials Inc. Demulsifier compositions and methods for separating emulsions using the same
US20130052259A1 (en) 2010-02-01 2013-02-28 Yechezkel Barenholz Liposomes comprising amphipathic drugs and method for their preparation
WO2011103528A2 (en) 2010-02-22 2011-08-25 Opko Curna Llc Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
KR20180028561A (en) 2010-02-23 2018-03-16 제넨테크, 인크. Anti-angiogenesis therapy for the treatment of ovarian cancer
EP2538981B1 (en) 2010-02-23 2017-12-20 F. Hoffmann-La Roche AG Compositions and methods for the diagnosis and treatment of tumor
MX2012009809A (en) 2010-02-23 2012-11-23 Sanofi Sa Anti-alpha2 integrin antibodies and their uses.
US8298535B2 (en) 2010-02-24 2012-10-30 Rinat Neuroscience Corp. Anti-IL-7 receptor antibodies
EP2538929A4 (en) 2010-02-25 2014-07-09 Univ Johns Hopkins Sustained delivery of therapeutic agents to an eye compartment
AU2011225716A1 (en) 2010-03-11 2012-09-27 Pfizer Inc. Antibodies with pH dependent antigen binding
WO2011119487A2 (en) 2010-03-22 2011-09-29 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations
EP2550000A4 (en) 2010-03-24 2014-03-26 Advirna Inc Reduced size self-delivering rnai compounds
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CA2794745A1 (en) 2010-03-29 2011-10-06 Zymeworks, Inc. Antibodies with enhanced or suppressed effector function
ES2893199T3 (en) 2010-03-29 2022-02-08 Alnylam Pharmaceuticals Inc dsRNA therapy for transthyretin (TTR)-related ocular amyloidosis
SG183947A1 (en) 2010-03-31 2012-10-30 Boehringer Ingelheim Int Anti-cd40 antibodies
WO2011123672A1 (en) 2010-03-31 2011-10-06 Pharmasset, Inc. Purine nucleoside phosphoramidate
KR101715981B1 (en) 2010-03-31 2017-03-13 길리애드 파마셋 엘엘씨 Nucleoside phosphoramidates
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
US9102938B2 (en) 2010-04-01 2015-08-11 Alnylam Pharmaceuticals, Inc. 2′ and 5′ modified monomers and oligonucleotides
US9073990B2 (en) 2010-04-05 2015-07-07 Bar-Llan University Protease-activatable pore-forming polypeptides
US9044494B2 (en) 2010-04-09 2015-06-02 Curna, Inc. Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
US20130260460A1 (en) 2010-04-22 2013-10-03 Isis Pharmaceuticals Inc Conformationally restricted dinucleotide monomers and oligonucleotides
US10913767B2 (en) 2010-04-22 2021-02-09 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
EP3085387A1 (en) 2010-04-26 2016-10-26 Abraxis BioScience, LLC Sparc binding antibodies and uses thereof
JP5787323B2 (en) * 2010-04-28 2015-09-30 国立大学法人北海道大学 Lipid membrane structure
WO2011139917A1 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Modulation of transthyretin expression
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
MX340696B (en) 2010-04-30 2016-07-21 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies.
MA34291B1 (en) 2010-05-03 2013-06-01 Genentech Inc COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A TUMOR
BR112012027828A2 (en) 2010-05-03 2016-08-09 Genentech Inc matter composition, article of manufacture and method of reducing the viscosity of a protein containing formulation and preparing an aqueous protein containing formulation
EP2566966A4 (en) 2010-05-03 2013-12-11 Curna Inc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
CN103429739B (en) 2010-05-12 2018-11-13 哥伦比亚大学纽约管理委员会 Prepare the method generated with the enteroendocrine cell of excreting insulin
TWI586356B (en) 2010-05-14 2017-06-11 可娜公司 Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
WO2011145035A1 (en) 2010-05-17 2011-11-24 Indian Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
EP2571516B1 (en) 2010-05-18 2017-11-15 Neumedicines, Inc Il-12 formulations for enhancing hematopoiesis
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
CA2799207C (en) 2010-05-26 2019-03-26 Curna, Inc. Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
ES2648885T3 (en) 2010-06-02 2018-01-08 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
WO2011153323A2 (en) 2010-06-02 2011-12-08 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis
DK2575764T3 (en) 2010-06-03 2017-08-07 Alnylam Pharmaceuticals Inc BIODEGRADABLE LIPIDS FOR THE ACTIVATION OF ACTIVE AGENTS
DK2582674T3 (en) 2010-06-16 2014-12-15 Cymabay Therapeutics Inc GPR120 receptor agonists and uses thereof.
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
WO2011160110A1 (en) * 2010-06-19 2011-12-22 Western University Of Health Sciences Novel formulation of pegylated-liposome encapsulated glycopeptide antibiotics
CA2802541A1 (en) 2010-06-23 2011-12-29 Metabolex, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
AU2011270828B2 (en) 2010-06-24 2015-09-24 Genentech, Inc. Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
CN102309448B (en) * 2010-06-29 2014-07-09 中国人民解放军军事医学科学院毒物药物研究所 Pulmonary delivery ciprofloxacin pharmaceutical composition and preparation method thereof
WO2012000104A1 (en) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
DK3243526T3 (en) 2010-07-06 2020-02-17 Glaxosmithkline Biologicals Sa SUPPLY OF RNA TO TRACT MULTIPLE IMMUNE SIGNAL WAYS
PT2591114T (en) 2010-07-06 2016-08-02 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of rna
SI2590676T1 (en) 2010-07-06 2016-11-30 Glaxosmithkline Biologicals, S.A. Virion-like delivery particles for self-replicating rna molecules
CN103153284B (en) 2010-07-06 2015-11-25 诺华股份有限公司 The liposome of the lipid of RNA delivery is conducive to containing its pKa value
ES2704223T3 (en) 2010-07-12 2019-03-15 Pfizer Healthcare Ireland Conjugates of multifunctional antibodies
US8980860B2 (en) 2010-07-14 2015-03-17 Curna, Inc. Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG
CN103261225A (en) 2010-07-23 2013-08-21 波士顿大学董事会 Anti-desupr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US8906943B2 (en) 2010-08-05 2014-12-09 John R. Cashman Synthetic compounds and methods to decrease nicotine self-administration
EP2420250A1 (en) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4 antibodies
WO2012021786A2 (en) 2010-08-12 2012-02-16 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
EP4101462A1 (en) * 2010-08-31 2022-12-14 GlaxoSmithKline Biologicals S.A. Pegylated liposomes for delivery of immunogen-encoding rna
ES2920140T3 (en) 2010-08-31 2022-08-01 Theraclone Sciences Inc Human immunodeficiency virus (HIV) neutralizing antibodies
CA2809678A1 (en) 2010-08-31 2012-03-08 Novartis Ag Small liposomes for delivery of immunogen-encoding rna
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US8481680B2 (en) 2010-10-05 2013-07-09 Genentech, Inc. Mutant smoothened and methods of using the same
US8993533B2 (en) 2010-10-06 2015-03-31 Curna, Inc. Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
ES2716243T3 (en) 2010-10-11 2019-06-11 Glaxosmithkline Biologicals Sa Antigen Supply Platforms
CA2815212A1 (en) 2010-10-22 2012-04-26 Curna, Inc. Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
EP2633317A1 (en) 2010-10-25 2013-09-04 Genentech, Inc. Treatment of gastrointestinal inflammation and psoriasis a
CN103201387B (en) 2010-10-27 2018-02-02 库尔纳公司 IFRD1 relevant diseases are treated by suppressing the natural antisense transcript of interferon correlative development regulatory factor 1 (IFRD1)
EA030436B1 (en) 2010-11-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх ANTI-IL-23p19 ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS THEREOF, USE THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THESE ANTIBODIES, METHOD FOR PRODUCING SAME, ISOLATED POLYNUCLEOTIDES, EXPRESSION VECTORS AND CELLS FOR PRODUCING ANTIBODIES
WO2012061811A2 (en) 2010-11-05 2012-05-10 Fibrogen, Inc. Treatment method for lung remodeling diseases
CN110123830A (en) 2010-11-09 2019-08-16 阿尔尼拉姆医药品有限公司 Composition and method for inhibiting the lipid of the expression of Eg5 and VEGF gene to prepare
US9518114B2 (en) 2010-11-12 2016-12-13 Purdue Research Foundation Treating bladder tumor cells using fibronectin attachment protein as a target
US20140199682A1 (en) 2010-11-17 2014-07-17 Sea Lane Biotechnologies, Llc Influenza neutralizing agents
CN103561726A (en) 2010-11-18 2014-02-05 通用医疗公司 Novel compositions and uses of anti-hypertension agents for cancer therapy
WO2012071238A2 (en) 2010-11-23 2012-05-31 Opko Curna Llc Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
EP3042910B1 (en) 2010-11-30 2019-01-09 Gilead Pharmasset LLC 2'-spiro-nucleosides for use in the therapy of hepatitis c
WO2012079046A2 (en) 2010-12-10 2012-06-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
WO2012078967A2 (en) 2010-12-10 2012-06-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for increasing erythropoietin (epo) production
KR20140092226A (en) 2010-12-14 2014-07-23 테크니칼 유니버시티 오브 덴마크 Entrapment of radionuclides in nanoparticle compositions
EP2468259A1 (en) * 2010-12-23 2012-06-27 Traslational Cancer Drugs Pharma, S.L. Pharmaceutical compositions of pyridinium and quinolinium derivatives
CA2834968C (en) 2011-01-05 2018-01-09 Livon Laboratories Methods of making liposomes, liposome compositions made by the methods, and methods of using the same
EP4215194A1 (en) 2011-01-11 2023-07-26 Dimerix Bioscience Pty Ltd Combination therapy
DK3202760T3 (en) 2011-01-11 2019-11-25 Alnylam Pharmaceuticals Inc PEGYLED LIPIDS AND THEIR USE FOR PHARMACEUTICAL SUPPLY
SI2670411T1 (en) 2011-02-02 2019-06-28 Excaliard Pharmaceuticals, Inc. Antisense compounds targeting connective tissue growth factor (ctgf) for use in a method of treating keloids or hypertrophic scars
RU2440142C1 (en) 2011-02-07 2012-01-20 Общество С Ограниченной Ответственностью "Онкомакс" Antibody, stopping or retarding tumour growth (versions), method of suppressing tumour growth, method of diagnosing malignant lesions
WO2012109495A1 (en) 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
EP2675478A4 (en) 2011-02-14 2015-06-10 Theraclone Sciences Inc Compositions and methods for the therapy and diagnosis of influenza
PL226015B1 (en) * 2011-03-03 2017-06-30 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Liposome preparation containing anticancer active substance, process for the preparation thereof and pharmaceutical compositions containing thereof
JP6211931B2 (en) 2011-03-09 2017-10-11 セル・シグナリング・テクノロジー・インコーポレイテツド Methods and reagents for producing monoclonal antibodies
BR112013023576A2 (en) 2011-03-15 2016-12-06 Theraclone Sciences Inc compositions and methods for influenza therapy and diagnosis
JP2014509859A (en) 2011-03-16 2014-04-24 アムジエン・インコーポレーテツド Potent and selective inhibitors of 17NAV1.3 and NAV1.7
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
US9181308B2 (en) 2011-03-28 2015-11-10 St. Jude Children's Research Hospital Methods and compositions employing immunogenic fusion proteins
SG193923A1 (en) 2011-03-29 2013-11-29 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of tmprss6 gene
AU2012236304C1 (en) 2011-03-31 2017-01-05 Genentech, Inc. Methods of administering beta7 integrin antagonists
EP2508176A1 (en) 2011-04-08 2012-10-10 Lipotarg Gmbh Novel combination treatment of cancer
CN103547588B (en) 2011-04-13 2016-06-29 Isis制药公司 The antisense that PTP1B expresses regulates
JP6072771B2 (en) 2011-04-20 2017-02-01 メディミューン，エルエルシー Antibodies and other molecules that bind to B7-H1 and PD-1
KR101589135B1 (en) 2011-04-20 2016-01-29 주식회사 셀앤바이오 Humanized anti-EMAPII antibodies and uses thereof
ES2710874T3 (en) 2011-05-04 2019-04-29 Rhizen Pharmaceuticals S A Novel compounds as modulators of protein kinases
JP6400470B2 (en) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド Multispecific Fab fusion proteins and methods of use
KR20190042747A (en) 2011-06-02 2019-04-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Methods and uses for ex vivo tissue culture systems
RU2620980C2 (en) 2011-06-09 2017-05-30 Курна, Инк. Treatment of diseases associated with frataxin (fxn), by inhibiting natural antisense fxn transcript
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2721156B1 (en) 2011-06-16 2016-12-21 Ionis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
CN112111492A (en) 2011-06-21 2020-12-22 阿尔尼拉姆医药品有限公司 Compositions and methods for inhibiting expression of apolipoprotein C-III (APOC3) gene
WO2012177949A2 (en) 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of expression of protein c (proc) genes
CA2839896A1 (en) 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc. Assays and methods for determining activity of a therapeutic agent in a subject
EP2537532A1 (en) 2011-06-22 2012-12-26 J. Stefan Institute Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use
WO2012178033A2 (en) 2011-06-23 2012-12-27 Alnylam Pharmaceuticals, Inc. Serpina1 sirnas: compositions of matter and methods of treatment
WO2013003112A1 (en) 2011-06-27 2013-01-03 The Jackson Laboratory Methods and compositions for treatment of cancer and autoimmune disease
US20150045540A1 (en) 2011-06-28 2015-02-12 Sea Lane Biotechnologies, Llc Multispecific stacked variable domain binding proteins
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
PL2731591T3 (en) 2011-07-13 2021-05-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Liposomes co-encapsulating a bisphosphonate and an amphipathic agent
US20140161821A1 (en) 2011-07-14 2014-06-12 Pfizer Inc. Treatment with anti-pcsk9 antibodies
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
WO2013015821A1 (en) 2011-07-22 2013-01-31 The Research Foundation Of State University Of New York Antibodies to the b12-transcobalamin receptor
US20130022551A1 (en) 2011-07-22 2013-01-24 Trustees Of Boston University DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
EP2739735A2 (en) 2011-08-01 2014-06-11 Alnylam Pharmaceuticals, Inc. Method for improving the success rate of hematopoietic stem cell transplants
WO2013025779A1 (en) 2011-08-15 2013-02-21 Amplimmune, Inc. Anti-b7-h4 antibodies and their uses
FR2979239A1 (en) * 2011-08-25 2013-03-01 Trophos LIPOSOME COMPRISING AT LEAST ONE CHOLESTEROL DERIVATIVE
WO2013033069A1 (en) 2011-08-30 2013-03-07 Theraclone Sciences, Inc. Human rhinovirus (hrv) antibodies
PT2751279T (en) 2011-08-31 2017-12-29 St Jude Children`S Res Hospital Methods and compositions to detect the level of lysosomal exocytosis activity and methods of use
MY170725A (en) 2011-09-09 2019-08-27 Univ Osaka Dengue-virus serotype neutralizing antibodies
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
AU2012312654B2 (en) 2011-09-19 2017-04-13 Gencia Corporation Modified creatine compounds
EP3401401B1 (en) 2011-09-20 2020-04-15 Ionis Pharmaceuticals, Inc. Antisense modulation of gcgr expression
US9399678B2 (en) 2011-09-23 2016-07-26 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Anti-tumor necrosis factor-alpha agents and uses thereof
EP2758438A1 (en) 2011-09-23 2014-07-30 Amgen Research (Munich) GmbH Bispecific binding molecules for 5t4 and cd3
HUE061002T2 (en) 2011-09-23 2023-04-28 Mereo Biopharma 5 Inc Vegf/dll4 binding agents and uses thereof
CA2849476A1 (en) 2011-09-27 2013-04-04 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
CA2850187C (en) 2011-09-29 2021-12-07 Plx Pharma Inc. Ph dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
CN113876945A (en) 2011-10-06 2022-01-04 免疫疫苗技术有限公司 Liposome composition comprising adjuvant for activating or increasing TLR2 activity and application thereof
ES2687951T3 (en) 2011-10-14 2018-10-30 F. Hoffmann-La Roche Ag Anti-HtrA1 antibodies and procedures for use
US8883989B2 (en) 2011-10-18 2014-11-11 Regents Of The University Of Minnesota Fractalkine binding polynucleotides and methods of use
CN103906838A (en) 2011-10-25 2014-07-02 Isis制药公司 Antisense modulation of GCCR expression
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
MX2014004991A (en) 2011-10-28 2014-05-22 Genentech Inc Therapeutic combinations and methods of treating melanoma.
DK3091029T3 (en) 2011-10-31 2023-01-30 Hoffmann La Roche Anti-IL13 antibody formulations
TWI619496B (en) * 2011-11-03 2018-04-01 台灣微脂體股份有限公司 Pharmaceutical compositions of hydrophobic camptothecin derivatives
US10980798B2 (en) 2011-11-03 2021-04-20 Taiwan Liposome Company, Ltd. Pharmaceutical compositions of hydrophobic camptothecin derivatives
BR112014011331A2 (en) 2011-11-11 2017-04-25 Rinat Neuroscience Corp trop-2 specific antibodies and their uses
TWI679212B (en) 2011-11-15 2019-12-11 美商安進股份有限公司 Binding molecules for e3 of bcma and cd3
PL2780373T3 (en) 2011-11-16 2020-03-31 Boehringer Ingelheim International Gmbh Anti il-36r antibodies
AU2012352454A1 (en) 2011-12-15 2014-07-17 The University Of Chicago Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors
EP2794659A1 (en) 2011-12-22 2014-10-29 Rinat Neuroscience Corp. Human growth hormone receptor antagonist antibodies and methods of use thereof
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
EP3539982A3 (en) 2011-12-23 2020-01-15 Pfizer Inc Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
EP3447071A1 (en) 2012-01-09 2019-02-27 Pfizer Healthcare Ireland Mutant antibodies and conjugation thereof
EP2804620A4 (en) 2012-01-18 2016-04-13 Neumedicines Inc Il-12 for radiation protection and radiation-induced toxicity mitigation
JP2015505537A (en) 2012-01-20 2015-02-23 シー レーン バイオテクノロジーズ， エルエルシー Binding molecule conjugate
US20150004219A1 (en) 2012-02-02 2015-01-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Stable liposomes for drug delivery
EP3578569A1 (en) 2012-02-06 2019-12-11 Inhibrx, Inc. Cd47 antibodies and methods of use thereof
AU2013221292A1 (en) * 2012-02-17 2014-09-11 Celsion Corporation Thermosensitive nanoparticle formulations and method of making the same
US9138492B2 (en) * 2012-02-23 2015-09-22 Canon Kabushiki Kaisha Particle containing hydrophobic dye having cyanine structure, and contrast agent containing the particle
US20150037334A1 (en) 2012-03-01 2015-02-05 Amgen Research (Munich) Gmbh Long life polypeptide binding molecules
US8865730B2 (en) 2012-03-05 2014-10-21 Gilead Calistoga Llc Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
JP2015511494A (en) 2012-03-15 2015-04-20 キュアナ，インク． Treatment of BDNF-related diseases by inhibition of natural antisense transcripts against brain-derived neurotrophic factor (BDNF)
PL2831117T3 (en) 2012-03-29 2018-03-30 Novimmune Sa Anti-tlr4 antibodies and uses thereof
SG11201406185WA (en) 2012-03-30 2014-11-27 Rhizen Pharmaceuticals Sa Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
US9133461B2 (en) 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
JP2015516400A (en) 2012-04-24 2015-06-11 ユニバーシティー オブ マイアミＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉａｍｉ Perforin 2 protection against invasive and multi-drug resistant pathogens
EP3326649B1 (en) 2012-05-03 2022-02-09 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
JP6411329B2 (en) 2012-05-04 2018-10-24 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Affinity matured anti-CCR4 humanized monoclonal antibody and methods of use
CA2872519C (en) 2012-05-04 2017-09-05 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
BR112014031421A2 (en) 2012-06-15 2017-06-27 Brigham & Womens Hospital Inc cancer treatment compositions and methods for producing them
WO2013192546A1 (en) 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and mehtods of using the same
ES2631608T3 (en) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Env-glycoprotein variant of HIV-1
JP2015524410A (en) * 2012-07-18 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Liposome composition of epoxy ketone-based proteasome inhibitor
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
CN110464709A (en) 2012-08-10 2019-11-19 德克萨斯州大学系统董事会 For treating the neuroprotective liposome composition and method of apoplexy
EP2885319B1 (en) 2012-08-14 2019-10-09 Nanyang Technological University Angiopoietin-like 4 antibody and a method of its use in cancer treatment
ES2848025T3 (en) 2012-09-04 2021-08-05 Eleison Pharmaceuticals LLC Prevention of lung cancer recurrence with lipid-complexed cisplatin
US20160136159A1 (en) 2012-09-17 2016-05-19 Chemedest Ltd. Method for Treating Peripheral Neuropathy
US9828434B2 (en) 2012-10-04 2017-11-28 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-PD-L1 antibodies and methods of use
MX2015003932A (en) 2012-10-05 2015-07-23 Genentech Inc Methods for diagnosing and treating inflammatory bowel disease.
CA2887711A1 (en) 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
JP6371294B2 (en) 2012-10-31 2018-08-08 オンコメッド ファーマシューティカルズ インコーポレイテッド Methods and monitoring of treatment with DLL4 antagonists
EP3725807A1 (en) 2012-12-03 2020-10-21 NovImmune SA Anti-cd47 antibodies and methods of use thereof
KR20150095809A (en) 2012-12-12 2015-08-21 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 Compositions and methods for treatment of cancer
CN105072981B (en) 2012-12-19 2017-10-24 纽约州立大学研究基金会 The composition and method of inclusion are discharged for induced with laser nanoparticle
AU2013361275B2 (en) 2012-12-19 2016-11-24 Amplimmune, Inc. Anti-human B7-H4 antibodies and their uses
ES2875957T3 (en) 2012-12-20 2021-11-11 Amgen Inc APJ receptor agonists and their uses
GB201223053D0 (en) 2012-12-20 2013-02-06 Medical Res Council Receptor
EP2935332B1 (en) 2012-12-21 2021-11-10 MedImmune, LLC Anti-h7cr antibodies
WO2014107731A1 (en) 2013-01-07 2014-07-10 Biomedical Research Models, Inc. Therapeutic vaccines for treating herpes simplex virus type 2 infections
US9920121B2 (en) 2013-01-25 2018-03-20 Amgen Inc. Antibodies targeting CDH19 for melanoma
JO3519B1 (en) 2013-01-25 2020-07-05 Amgen Inc Antibody constructs for CDH19 and CD3
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
SG11201506132PA (en) 2013-02-06 2015-09-29 Inhibrx Llc Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
WO2014126921A1 (en) 2013-02-12 2014-08-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that neutralize norovirus
EP2970408B1 (en) 2013-03-12 2018-01-10 Amgen Inc. Potent and selective inhibitors of nav1.7
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
JP2016513712A (en) 2013-03-14 2016-05-16 ジェローム， ジェイ． シェンターク， Cholestosome vesicles for uptake of molecules into chylomicrons
EP3689902B1 (en) 2013-03-15 2023-06-28 Dana-Farber Cancer Institute, Inc. Flavivirus neutralizing antibodies and methods of use thereof
WO2014140368A1 (en) 2013-03-15 2014-09-18 Amgen Research (Munich) Gmbh Antibody constructs for influenza m2 and cd3
WO2014144017A2 (en) 2013-03-15 2014-09-18 Gencia Corporation Compositions and methods for treating conditions that affect epidermis
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
WO2014152497A2 (en) 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for cognitive disorders
JP2016513682A (en) 2013-03-15 2016-05-16 ダイアックス コーポレーション Anti-plasma kallikrein antibody
WO2014145654A1 (en) 2013-03-15 2014-09-18 The Trustees Of The University Of Pennsylvania Method for the site-specific covalent cross-linking of antibodies to surfaces
US10159688B2 (en) * 2013-03-15 2018-12-25 M. Alphabet 3, L.L.C. Methods and compositions for enhancing oxygen levels in tissues
AR095374A1 (en) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh UNION MOLECULES FOR BCMA AND CD3
EP3653642A1 (en) 2013-03-15 2020-05-20 Amgen Research (Munich) GmbH Single chain binding molecules comprising n-terminal abp
KR102175688B1 (en) 2013-03-27 2020-11-06 제넨테크, 인크. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
EP2978446B1 (en) 2013-03-27 2020-03-04 The General Hospital Corporation Anti-cd33 antibody for use in treating alzheimer's disease
DK2983787T3 (en) 2013-04-12 2020-01-06 Icahn School Med Mount Sinai Procedure for the treatment of post-traumatic stress disorder
US20140329889A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
EP2994167B1 (en) 2013-05-06 2020-05-06 Alnylam Pharmaceuticals, Inc. Dosages and methods for delivering lipid formulated nucleic acid molecules
WO2014182676A2 (en) 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation
SG11201508264UA (en) 2013-05-07 2015-11-27 Rinat Neuroscience Corp Anti-glucagon receptor antibodies and methods of use thereof
WO2014183052A1 (en) 2013-05-09 2014-11-13 The United States Of America, As Represented By The Secretary, Depart Of Health And Human Services Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use
BR112015029395A2 (en) 2013-05-24 2017-09-19 Medimmune Llc ANTI-B7-H5 ANTIBODIES AND THEIR USES
RU2687044C2 (en) 2013-05-31 2019-05-06 Дженентек, Инк. Antibodies against teichoic acid conjugate and their conjugates
PE20160715A1 (en) 2013-05-31 2016-08-01 Genentech Inc ANTIBODIES AGAINST WALL AND CONJUGATED TEICOIC ACIDS
ES2891755T3 (en) 2013-06-06 2022-01-31 Pf Medicament Anti-C10orf54 antibodies and uses thereof
AU2014280847B2 (en) 2013-06-13 2019-07-04 Antisense Therapeutics Ltd Combination therapy
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
AU2014292924B2 (en) 2013-07-25 2019-11-21 Cytomx Therapeutics, Inc Multispecific antibodies, multispecific activatable antibodies and methods of using the same
US20160193148A1 (en) * 2013-08-01 2016-07-07 University Of Georgia Research Foundation, Inc. Liposomal formulations for the treatment of bacterial infections
TWI623551B (en) 2013-08-02 2018-05-11 輝瑞大藥廠 Anti-cxcr4 antibodies and antibody-drug conjugates
EA201690213A1 (en) 2013-08-12 2016-07-29 Дженентек, Инк. COMPOSITIONS AND METHOD FOR TREATMENT OF CONNECTED STATES
US10077304B2 (en) 2013-08-14 2018-09-18 The Governing Council Of The University Of Toronto Antibodies against frizzled receptor
WO2015031536A1 (en) * 2013-08-27 2015-03-05 Northeastern University Nanoparticle drug delivery system and method of treating cancer and neurotrauma
ES2779302T3 (en) 2013-09-04 2020-08-14 Cold Spring Harbor Laboratory Reduction of mRNA degradation with nonsense mediation
AU2014317961B2 (en) 2013-09-05 2020-07-30 Murdoch University Antisense-induced exon2 inclusion in acid alpha-glucosidase
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
TWI688401B (en) 2013-09-13 2020-03-21 美商安進公司 Combination of epigenetic factors and bispecific compounds targeting cd33 and cd3 in the treatment of myeloid leukemia
PT3046537T (en) * 2013-09-16 2021-10-07 Glycomine Inc Pharmaceutical preparation of carbohydrates for therapeutic use
DE102013015334A1 (en) * 2013-09-17 2015-03-19 Fresenius Medical Care Deutschland Gmbh Magnesium-liposome complexes
US10036020B2 (en) 2013-09-19 2018-07-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for inhibiting JC virus (JCV)
RU2020106752A (en) 2013-09-25 2020-03-11 Сайтомкс Терапьютикс, Инк. SUBSTRATES OF MATRIX METALLOPROTEINASES AND OTHER DISSOLIDABLE FRAGMENTS AND METHODS FOR USING THEM
ES2714708T3 (en) 2013-10-01 2019-05-29 Mayo Found Medical Education & Res Procedures for the treatment of cancer in patients with elevated levels of Bim
CN105793423A (en) 2013-10-02 2016-07-20 阿尔尼拉姆医药品有限公司 Compositions and methods for inhibiting expression of the LECT2 gene
JP6613227B2 (en) 2013-10-04 2019-11-27 アルナイラム ファーマシューティカルズ， インコーポレイテッド Composition and method for inhibiting the expression of ALAS1 gene
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3070167A4 (en) 2013-11-06 2017-06-07 Osaka University Antibody having broad neutralizing activity in group 1 influenza a virus
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
JP2017505756A (en) 2013-12-13 2017-02-23 ザ ジェネラル ホスピタル コーポレイション Soluble high molecular weight (HMW) tau species and uses thereof
WO2015095601A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
JP2017500319A (en) 2013-12-20 2017-01-05 ギリアード カリストガ エルエルシー Polymorphic form of the hydrochloride salt of (S) -2- (1- (9H-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3H) -one
CA2936940C (en) 2014-01-14 2023-07-04 The Johns Hopkins University Cyclodextrin compositions encapsulating a selective atp inhibitor and uses thereof
EP4176896A1 (en) 2014-01-31 2023-05-10 Cytomx Therapeutics Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
EA033604B1 (en) 2014-01-31 2019-11-08 Boehringer Ingelheim Int Anti-baff antibody molecule, pharmaceutical composition comprising this molecule, methods of using same and isolated polynucleotide encoding same
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
EP3102197B1 (en) 2014-02-04 2018-08-29 Genentech, Inc. Mutant smoothened and methods of using the same
US10272117B2 (en) 2014-02-24 2019-04-30 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
EP4043489A1 (en) 2014-03-19 2022-08-17 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
EP3119431B1 (en) 2014-03-21 2024-01-24 Teva Pharmaceuticals International GmbH Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
AU2015235986B2 (en) 2014-03-27 2020-12-03 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
US10426753B2 (en) 2014-04-03 2019-10-01 Invictus Oncology Pvt. Ltd. Supramolecular combinatorial therapeutics
EP3134111B1 (en) 2014-04-25 2022-06-08 Dana-Farber Cancer Institute, Inc. Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
LT3137114T (en) 2014-04-30 2021-03-25 Pfizer Inc. Anti-ptk7 antibody-drug conjugates
EP3139955B1 (en) 2014-04-30 2024-03-20 President and Fellows of Harvard College Fusion proteins for treating cancer and related methods
WO2015171918A2 (en) 2014-05-07 2015-11-12 Louisiana State University And Agricultural And Mechanical College Compositions and uses for treatment thereof
US10392438B2 (en) 2014-05-16 2019-08-27 Pfizer Inc. Bispecific antibodies
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
EA028614B1 (en) 2014-05-22 2017-12-29 Общество С Ограниченной Ответственностью "Русские Фармацевтические Технологии" Selective inhibitors interfering with fibroblast growth factor receptor and frs2 interaction for the prevention and treatment of cancer
US10584171B2 (en) 2014-05-30 2020-03-10 Henlix Biotech Co., Ltd. Anti-epidermal growth factor receptor (EGFR) antibodies
CA2951391C (en) 2014-06-10 2021-11-02 Amgen Inc. Apelin polypeptides
WO2015191362A1 (en) 2014-06-11 2015-12-17 Gilead Sciences, Inc. Methods for treating cardiovascular diseases
CA2952012A1 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
TWI695011B (en) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 Monoclonal antibodies against her2 epitope and methods of use thereof
EP3157945A4 (en) 2014-06-20 2017-11-22 F. Hoffmann-La Roche AG Chagasin-based scaffold compositions, methods, and uses
EP3160503B1 (en) 2014-06-26 2021-02-17 The Trustees of Columbia University in the City of New York Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
JP7020909B2 (en) 2014-07-25 2022-02-16 シトムクス セラピューティクス，インコーポレイティド Anti-CD3 antibody, activating anti-CD3 antibody, multispecific anti-CD3 antibody, multispecific activating anti-CD3 antibody, and how to use them.
UY36245A (en) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh ANTIBODY CONSTRUCTS FOR CDH19 AND CD3
US11661462B2 (en) 2014-07-31 2023-05-30 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody contructs
WO2016020798A1 (en) 2014-08-06 2016-02-11 Rinat Neuroscience Corp. Methods for reducing ldl-cholesterol
WO2016020799A1 (en) 2014-08-06 2016-02-11 Rinat Neuroscience Corp. Methods for reducing ldl-cholesterol
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
WO2016034968A1 (en) 2014-09-02 2016-03-10 Pfizer Inc. Therapeutic antibody
EP3197492A1 (en) 2014-09-23 2017-08-02 Pfizer Inc Treatment with anti-pcsk9 antibodies
EP3201232A1 (en) 2014-10-03 2017-08-09 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
WO2016057488A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
DK3212233T3 (en) 2014-10-31 2020-07-27 Oncomed Pharm Inc COMBINATION THERAPY FOR TREATMENT OF DISEASE
EP3218005B1 (en) 2014-11-12 2023-01-04 Seagen Inc. Glycan-interacting compounds and methods of use
WO2016077566A1 (en) 2014-11-12 2016-05-19 Research Institute At Nationwide Children's Hospital Modulation of alternative mdm2 splicing
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US11191811B2 (en) 2014-11-19 2021-12-07 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for frailty associated with aging
WO2016090038A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
JP6751393B2 (en) 2014-12-03 2020-09-02 ジェネンテック， インコーポレイテッド Anti-STAPHYLOCOCCUS AUREUS antibody rifamycin conjugate and use thereof
US10072070B2 (en) 2014-12-05 2018-09-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Potent anti-influenza A neuraminidase subtype N1 antibody
TWI595006B (en) 2014-12-09 2017-08-11 禮納特神經系統科學公司 Anti-pd-1 antibodies and methods of use thereof
PT3800202T (en) 2014-12-11 2023-01-05 Pf Medicament Anti-c10orf54 antibodies and uses thereof
TW201702218A (en) 2014-12-12 2017-01-16 美國杰克森實驗室 Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease
CN107278151A (en) 2014-12-15 2017-10-20 约翰霍普金斯大学 Sutent preparation and its application method in treatment glaucoma
JP2018504380A (en) 2014-12-18 2018-02-15 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． REVERSIR ™ compounds
EP3797789A1 (en) 2015-01-20 2021-03-31 The Children's Medical Center Corporation Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing
MA41374A (en) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc MATRIX METALLOPROTEASE CLIVABLE AND SERINE PROTEASE CLIVABLE SUBSTRATES AND METHODS OF USE THEREOF
CA2974715C (en) 2015-01-27 2020-05-05 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
WO2016123329A2 (en) 2015-01-28 2016-08-04 Genentech, Inc. Gene expression markers and treatment of multiple sclerosis
JP2018506526A (en) 2015-01-29 2018-03-08 ボード オブ トラスティーズ オブ ミシガン ステイト ユニバーシティＢｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｍｉｃｈｉｇａｎ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Cryptic polypeptides and uses thereof
CA2976912A1 (en) * 2015-02-17 2016-08-25 Mallinckrodt Llc Modified docetaxel liposome formulations and uses thereof
US10550173B2 (en) 2015-02-19 2020-02-04 Compugen, Ltd. PVRIG polypeptides and methods of treatment
PL3258951T3 (en) 2015-02-19 2020-07-27 Compugen Ltd. Anti-pvrig antibodies and methods of use
AU2016222683A1 (en) 2015-02-26 2017-07-13 Genentech, Inc. Integrin beta7 antagonists and methods of treating crohn's disease
BR112017015880A2 (en) 2015-03-03 2018-07-31 Kymab Ltd antibodies, uses and methods
EP3265059A4 (en) 2015-03-03 2018-08-29 Cureport Inc. Combination liposomal pharmaceutical formulations
CN107530291A (en) * 2015-03-03 2018-01-02 奎尔波特股份有限公司 Double heavy duty liposomal pharmaceutical preparations
WO2016149201A2 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
AU2016233143B2 (en) 2015-03-17 2021-03-25 Alberto Gabizon Methods for the treatment of bladder cancer
MA41795A (en) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc EXCLUSION OF AN EXON INDUCED BY ANTISENSE COMPOUNDS IN MYOSTATIN
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
EP3280730B1 (en) 2015-04-08 2024-01-03 Dana-Farber Cancer Institute, Inc. Humanized influenza monoclonal antibodies and methods of use thereof
KR102405104B1 (en) 2015-04-13 2022-06-07 화이자 인코포레이티드 Therapeutic antibodies and their uses
KR20180023892A (en) 2015-04-17 2018-03-07 암젠 리서치 (뮌헨) 게엠베하 The bispecific antibody constructs for CDH3 and CD3
CN107849134B (en) 2015-05-01 2022-05-03 达纳－法伯癌症研究所公司 Methods of mediating cytokine expression with anti-CCR 4 antibodies
CN107922490A (en) 2015-05-04 2018-04-17 西托姆克斯治疗公司 Anti- ITGa3 antibody, can activate anti-ITGa3 antibody and its application method
HUE057720T2 (en) 2015-05-04 2022-06-28 Cytomx Therapeutics Inc Activatable anti-cd71 antibodies, and methods of use thereof
PT3292150T (en) 2015-05-04 2020-06-01 Cytomx Therapeutics Inc Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
EP3294334B1 (en) 2015-05-11 2020-07-08 The Johns Hopkins University Autoimmune antibodies for use in inhibiting cancer cell growth
EP3294887A1 (en) 2015-05-14 2018-03-21 CNIC Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III Mirna compositions for the treatment of mature b-cell neoplasms
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
AU2016271142A1 (en) 2015-05-29 2017-11-23 Genentech, Inc. PD-L1 promoter methylation in cancer
MA50829A (en) 2015-06-01 2018-04-11 Sarepta Therapeutics Inc EXCLUSION OF EXON INDUCED BY ANTISEN TECHNOLOGY IN TYPE VII COLLAGEN
MX2017016024A (en) 2015-06-10 2018-08-15 Elysium Health Inc Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders.
WO2017004538A1 (en) 2015-07-02 2017-01-05 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
CA2991976A1 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
DK3322733T3 (en) 2015-07-13 2021-10-18 Compugen Ltd HIDE1 COMPOSITIONS AND METHODS
EP3919619A1 (en) 2015-07-17 2021-12-08 Alnylam Pharmaceuticals, Inc. Multi-targeted single entity conjugates
US10913802B2 (en) 2015-07-21 2021-02-09 Dyax Corp. Monoclonal antibody inhibitor of factor XIIA
BR112018001762A2 (en) 2015-07-29 2018-09-18 Allergan Inc heavy chain only antibodies to ang-2
TWI717375B (en) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Antibody constructs for cd70 and cd3
TW202346349A (en) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Antibody constructs for dll3 and cd3
TWI829617B (en) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Antibody constructs for flt3 and cd3
TWI744242B (en) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Antibody constructs for egfrviii and cd3
TWI796283B (en) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Antibody constructs for msln and cd3
JP2018523673A (en) 2015-08-14 2018-08-23 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Heavy chain only antibody against PDGF
CN108348480A (en) 2015-08-20 2018-07-31 益普生生物制药有限公司 Use liposome Irinotecan and PARP inhibitor combination treatment use for cancer treatment
ES2826826T3 (en) 2015-08-21 2021-05-19 Ipsen Biopharm Ltd Pharmaceutical combination comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil and leucovorin for the treatment of metastatic pancreatic cancer
HUE063528T2 (en) 2015-09-01 2024-01-28 Boehringer Ingelheim Int Use of anti-cd40 antibodies for treatment of lupus nephritis
WO2017048843A1 (en) 2015-09-14 2017-03-23 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the alas1 gene
AU2016323447B2 (en) 2015-09-15 2023-03-30 Scholar Rock, Inc. Anti-pro/latent-Myostatin antibodies and uses thereof
TWI799366B (en) 2015-09-15 2023-04-21 美商建南德克公司 Cystine knot scaffold platform
CA2999160A1 (en) 2015-09-23 2017-03-30 Oncomed Pharmaceuticals, Inc. Methods and compositions for treatment of cancer
US10954300B2 (en) 2015-09-28 2021-03-23 The Trustees Of Columbia University In The City Of New York Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
WO2017055966A1 (en) 2015-10-01 2017-04-06 Pfizer Inc. Low viscosity antibody compositions
KR20180075537A (en) 2015-10-06 2018-07-04 제넨테크, 인크. Methods for treating multiple sclerosis
WO2017062835A2 (en) 2015-10-09 2017-04-13 Sarepta Therapeutics, Inc. Compositions and methods for treating duchenne muscular dystrophy and related disorders
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
SG10201912568PA (en) 2015-10-16 2020-02-27 Ipsen Biopharm Ltd Stabilizing camptothecin pharmaceutical compositions
WO2017066714A1 (en) 2015-10-16 2017-04-20 Compugen Ltd. Anti-vsig1 antibodies and drug conjugates
WO2017075037A1 (en) 2015-10-27 2017-05-04 Scholar Rock, Inc. Primed growth factors and uses thereof
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1
SI3368578T1 (en) 2015-10-30 2021-08-31 F. Hoffmann-La Roche Ag Anti-htra1 antibodies and methods of use thereof
WO2017075670A1 (en) 2015-11-05 2017-05-11 Children's Hospital Los Angeles "mobilizing leukemia cells"
EP3370712A4 (en) 2015-11-06 2019-10-09 The Johns Hopkins University Methods of treating liver fibrosis by administering 3-bromopyruvate
AU2016352874B2 (en) 2015-11-10 2021-06-24 Children's Research Institute, Children's National Medical Center Echinomycin formulation, method of making and method of use thereof
CA3004886A1 (en) 2015-11-12 2017-05-18 Graybug Vision, Inc. Aggregating microparticles for medical therapy
MX2018005061A (en) 2015-11-12 2019-02-28 Siamab Therapeutics Inc Glycan-interacting compounds and methods of use.
TWI778491B (en) 2015-11-30 2022-09-21 美商輝瑞股份有限公司 Site specific her2 antibody drug conjugates
TWI812873B (en) 2015-11-30 2023-08-21 美商輝瑞股份有限公司 Antibodies and antibody fragments for site-specific conjugation
ES2861449T3 (en) 2015-12-02 2021-10-06 Stcube & Co Inc Antibodies and Molecules that Immunospecifically Bind to BTN1A1 and Their Therapeutic Uses
WO2017096017A1 (en) 2015-12-02 2017-06-08 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
MA43415A (en) 2015-12-09 2018-10-17 Modernatx Inc MODIFIED RNA CODING FOR A URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE AND ASSOCIATED USES
US10548844B2 (en) 2015-12-14 2020-02-04 Massachusetts Institute Of Technology pH-responsive mucoadhesive polymeric encapsulated microorganisms
WO2017106630A1 (en) 2015-12-18 2017-06-22 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
WO2017110772A1 (en) 2015-12-21 2017-06-29 富士フイルム株式会社 Liposome and liposome composition
WO2017117218A1 (en) 2015-12-30 2017-07-06 Momenta Pharmaceuticals, Inc. Methods related to biologics
EP3400240A2 (en) 2016-01-08 2018-11-14 Scholar Rock, Inc. Anti-pro/latent myostatin antibodies and methods of use thereof
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
TWI797073B (en) 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 Pharmaceutical composition comprising bispecific antibody constructs
EA039859B1 (en) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Bispecific antibody constructs binding egfrviii and cd3
EP4039709A1 (en) 2016-02-03 2022-08-10 Amgen Research (Munich) GmbH Bcma and cd3 bispecific t cell engaging antibody constructs
IL260920B (en) 2016-02-03 2022-09-01 Amgen Res Munich Gmbh Psma and cd3 bispecific t cell engaging antibody constructs, compositions comprising same and uses thereof
AU2017213826A1 (en) 2016-02-04 2018-08-23 Curis, Inc. Mutant smoothened and methods of using the same
EP3426306A1 (en) * 2016-03-07 2019-01-16 Memorial Sloan Kettering Cancer Center Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use
JP7157981B2 (en) 2016-03-07 2022-10-21 チャールストンファーマ， エルエルシー anti-nucleolin antibody
PL3365368T3 (en) 2016-03-11 2023-08-21 Scholar Rock, Inc. Tgfbeta1-binding immunoglobulins and use thereof
CN109476756B (en) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 Multi-specificity Fab fusion protein and application thereof
CN109414511B (en) 2016-04-18 2023-05-23 萨勒普塔医疗公司 Antisense oligomers for treating diseases associated with acid alpha-glucosidase genes and methods of use thereof
US10973748B2 (en) 2016-04-21 2021-04-13 Versitech Limited Compositions and methods for lightening skin and reducing hyperpigmentation
US11365256B2 (en) 2016-06-08 2022-06-21 Xencor, Inc. Methods and compositions for inhibiting CD32B expressing cells in IGG4-related diseases
ITUA20164630A1 (en) 2016-06-23 2017-12-23 Paolo Blasi PHARMACOLOGICAL ADIUVANTS FOR TUMOR THERMAL WELDING
EP3474886B1 (en) 2016-06-27 2021-08-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children and adolescents
US11246832B2 (en) 2016-06-28 2022-02-15 Verily Life Sciences Llc Serial filtration to generate small cholesterol-containing liposomes
RU2019104896A (en) 2016-07-22 2020-08-24 Дана-Фарбер Кэнсер Инститьют, Инк. ANTIBODIES TO THE GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND METHODS OF THEIR USE
CN109862896A (en) 2016-08-03 2019-06-07 西玛贝医药公司 For treating the Oxymethylene aryl compound of inflammatory gastrointestinal disease or gastrointestinal disorder
TWI754659B (en) 2016-08-08 2022-02-11 台灣微脂體股份有限公司 Delivery vehicle, method and kit for preparing a liposomal composition containing mild acidic agent
US10870694B2 (en) 2016-09-02 2020-12-22 Dana Farber Cancer Institute, Inc. Composition and methods of treating B cell disorders
EP3509633A1 (en) 2016-09-06 2019-07-17 Dana-Farber Cancer Institute, Inc. Methods of treating or preventing zika virus infection
TW201825511A (en) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 Oncolytic virus expressing immune checkpoint modulators
JP2019534858A (en) 2016-09-09 2019-12-05 ジェネンテック， インコーポレイテッド Selective peptide inhibitor of FRIZZLED
AU2017325839A1 (en) 2016-09-14 2019-04-04 The Trustees Of The University Of Pennsylvania Proximity-based sortase-mediated protein purification and ligation
WO2018052818A1 (en) 2016-09-16 2018-03-22 Henlix, Inc. Anti-pd-1 antibodies
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
EA201990548A1 (en) 2016-09-23 2019-09-30 Тева Фармасьютикалз Интернэшнл Гмбх TREATMENT OF CLUSTER HEAD PAIN
KR20190086681A (en) 2016-10-26 2019-07-23 모더나티엑스, 인크. Messenger ribonucleic acid and method of use thereof for improving immune response
MX2019004783A (en) 2016-11-02 2019-08-12 Ipsen Biopharm Ltd Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin).
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
JP2020503256A (en) 2016-11-04 2020-01-30 ノビミューン エスアー Anti-CD19 antibodies and methods of using them
CN109996809A (en) 2016-11-14 2019-07-09 诺华股份有限公司 Composition relevant to fusogenic protein MINION, method and therapeutical uses
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. Glycan-interacting compounds and methods of use
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
US10772926B2 (en) 2016-12-16 2020-09-15 Nutragen Health Innovations, Inc. Natural drugs for the treatment of inflammation and melanoma
RS63849B9 (en) 2016-12-16 2023-06-30 Pfizer Glp-1 receptor agonists and uses thereof
JP7157744B2 (en) 2017-01-06 2022-10-20 スカラー ロック インコーポレイテッド Isoform-specific, context-tolerant TGFβ1 inhibitors and uses thereof
PL3565592T3 (en) 2017-01-06 2023-08-21 Scholar Rock, Inc. Treating metabolic diseases by inhibiting myostatin activation
PT3565592T (en) 2017-01-06 2023-05-31 Scholar Rock Inc Methods for treating metabolic diseases by inhibiting myostatin activation
WO2018144775A1 (en) 2017-02-01 2018-08-09 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
JOP20190189A1 (en) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh Low ph pharmaceutical composition comprising t cell engaging antibody constructs
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
BR112019018043A2 (en) 2017-03-03 2020-04-07 Seattle Genetics Inc cancer treatment method, and, antibody-drug conjugate
SG11201907835YA (en) 2017-03-03 2019-09-27 Rinat Neuroscience Corp Anti-gitr antibodies and methods of use thereof
KR20190134654A (en) 2017-03-09 2019-12-04 싸이톰스 테라퓨틱스, 인크. CD147 antibody, activatable CD147 antibody, and how to make and use it
CN110461877A (en) 2017-03-27 2019-11-15 勃林格殷格翰国际有限公司 The anti-antibody combined treatment of IL-36R
WO2018191153A1 (en) 2017-04-09 2018-10-18 The Cleveland Clinic Foundation Cancer treatment by malat1 inhibition
WO2018189611A1 (en) 2017-04-12 2018-10-18 Pfizer Inc. Antibodies having conditional affinity and methods of use thereof
CA3059938A1 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
EP3612625A4 (en) 2017-04-21 2021-08-18 Mellitus, LLC Methods and antibodies for diabetes-related applications
EP3615569A1 (en) 2017-04-25 2020-03-04 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
KR20190141243A (en) 2017-05-05 2019-12-23 암젠 인크 Pharmaceutical compositions comprising bispecific antibody constructs for improved storage and administration
US11318190B2 (en) 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease
AU2018265415A1 (en) 2017-05-10 2019-10-31 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
WO2018209288A1 (en) 2017-05-12 2018-11-15 Massachusetts Institute Of Technology Argonaute protein-double stranded rna complexes and uses related thereto
SG11201909751TA (en) 2017-05-12 2019-11-28 Augusta University Research Institute Inc Human alpha fetoprotein-specific t cell receptors and uses thereof
EP3630167A1 (en) 2017-05-26 2020-04-08 NovImmune SA Anti-cd47 x anti-mesothelin antibodies and methods of use thereof
US20200131266A1 (en) 2017-05-31 2020-04-30 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
KR20200015602A (en) 2017-05-31 2020-02-12 주식회사 에스티큐브앤컴퍼니 Antibodies and molecules immunospecifically binding to BTN1A1 and therapeutic uses thereof
US11168144B2 (en) 2017-06-01 2021-11-09 Cytomx Therapeutics, Inc. Activatable anti-PDL1 antibodies, and methods of use thereof
KR20200026209A (en) 2017-06-06 2020-03-10 주식회사 에스티큐브앤컴퍼니 How to treat cancer using antibodies and molecules that bind BTN1A1 or BTN1A1-ligand
GB201710838D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
PE20200746A1 (en) 2017-07-06 2020-07-24 Arrowhead Pharmaceuticals Inc IARN AGENTS FOR THE INHIBITION OF THE EXPRESSION OF ALFA-ENAC AND METHODS OF USE
US20190015473A1 (en) 2017-07-13 2019-01-17 Massachusetts Institute Of Technology Targeting the hdac2-sp3 complex to enhance synaptic funcation
KR20200027971A (en) 2017-07-14 2020-03-13 싸이톰스 테라퓨틱스, 인크. Anti-CD166 antibodies and uses thereof
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
US20210025877A1 (en) 2017-07-20 2021-01-28 CytomX Therapeutices, Inc. Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra Anti-nucleolin antibody
MA49634A (en) 2017-07-21 2020-05-27 Modernatx Inc MODIFIED RNA CODING FOR A PROPIONYL-COA-CARBOXYLASE AND ASSOCIATED USES
EP3658672A1 (en) 2017-07-24 2020-06-03 Modernatx, Inc. Modified mrna encoding a glucose-6-phosphatase and uses thereof
CN116271012A (en) 2017-07-27 2023-06-23 瑞颂医药公司 High concentration anti-C5 antibody formulations
US20200231682A1 (en) 2017-07-28 2020-07-23 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
AU2018310857A1 (en) 2017-08-03 2020-02-13 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof
US11135187B2 (en) 2017-08-22 2021-10-05 National Institutes Of Health (Nih) Compositions and methods for treating diabetic retinopathy
US20190117789A1 (en) 2017-08-30 2019-04-25 Cytomx Therapeutics, Inc. Activatable anti-cd166 antibodies and methods of use thereof
CN111133005A (en) 2017-09-07 2020-05-08 奥古斯塔大学研究所公司 Programmed cell death protein 1 antibodies
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
JP2020536967A (en) 2017-10-12 2020-12-17 イミュノウェイク インコーポレイテッド VEGFR-antibody light chain fusion protein
CA3078911A1 (en) 2017-10-14 2019-04-18 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
SG11202003434SA (en) 2017-10-17 2020-05-28 Rhizen Pharmaceuticals Sa Crac channel modulators for treating esophageal cancer
JP7394753B2 (en) 2017-10-18 2023-12-08 サレプタ セラピューティクス， インコーポレイテッド antisense oligomer compounds
WO2019082124A1 (en) 2017-10-26 2019-05-02 Rhizen Pharmaceuticals Sa Composition and method for treating diffuse large b-cell lymphoma
CN111556876A (en) 2017-10-27 2020-08-18 辉瑞公司 Antibodies and antibody-drug conjugates specific for CD123 and uses thereof
EA202090682A1 (en) 2017-10-30 2020-10-15 Ризен Фармасьютикалз Са CALCIUM CHANNEL MODULATORS ACTIVATED BY CALCIUM RELEASE FOR TREATMENT OF HEMATOLOGICAL AND SOLID CANCER DISEASES
WO2019086626A1 (en) 2017-11-03 2019-05-09 Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) MIRNAs AND COMBINATIONS THEREOF FOR USE IN THE TREATMENT OF HUMAN B CELL NEOPLASIAS
US20200289520A1 (en) 2017-12-06 2020-09-17 Rhizen Pharmaceuticals Sa Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma
US11946094B2 (en) 2017-12-10 2024-04-02 Augusta University Research Institute, Inc. Combination therapies and methods of use thereof
US20210163592A1 (en) 2017-12-11 2021-06-03 Amgen Inc Continuous manufacturing process for bispecific antibody products
TW201940518A (en) 2017-12-29 2019-10-16 美商安進公司 Bispecific antibody construct directed to MUC17 and CD3
US20190254973A1 (en) 2018-02-22 2019-08-22 Verily Life Sciences Llc Combining orthogonal chemistries for preparation of multiplexed nanoparticles
RU2020128440A (en) 2018-02-28 2022-03-28 Пфайзер Инк. IL-15 OPTIONS AND THEIR APPLICATIONS
EP3762420A1 (en) 2018-03-09 2021-01-13 CytomX Therapeutics, Inc. Activatable cd147 antibodies and methods of making and use thereof
CA3093330A1 (en) 2018-03-14 2019-09-19 Novimmune Sa Anti-cd3 epsilon antibodies and methods of use thereof
AU2019235033A1 (en) 2018-03-14 2020-07-30 Beijing Xuanyi Pharmasciences Co., Ltd. Anti-claudin 18.2 antibodies
CA3093723A1 (en) 2018-03-21 2019-09-26 Colorado State University Research Foundation Cancer vaccine compositions and methods of use thereof
US10722528B2 (en) 2018-03-28 2020-07-28 Augusta University Research Institute, Inc. Compositions and methods for inhibiting metastasis
CN112334485A (en) 2018-04-06 2021-02-05 百进生物科技公司 Anti-tetraspanin 33agents and compositions thereof and methods of making and using
CN116536272A (en) 2018-04-06 2023-08-04 儿童医疗中心有限公司 Compositions and methods for somatic reprogramming and imprinting
US20210115156A1 (en) 2018-04-13 2021-04-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Fc-engineered anti-human ige antibodies and methods of use
US20210171610A1 (en) 2018-05-02 2021-06-10 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
PE20210127A1 (en) 2018-05-23 2021-01-19 Pfizer CD3 SPECIFIC ANTIBODIES AND THEIR USES
US11525010B2 (en) 2018-05-23 2022-12-13 Pfizer Inc. Antibodies specific for GUCY2c and uses thereof
CA3045370A1 (en) 2018-06-08 2019-12-08 Pfizer Inc. Methods of treating metabolic disease
TWI707683B (en) 2018-06-13 2020-10-21 美商輝瑞股份有限公司 Glp-1 receptor agonists and uses thereof
MX2020013624A (en) 2018-06-15 2022-08-11 Pfizer Glp-1 receptor agonists and uses thereof.
WO2019245817A1 (en) 2018-06-19 2019-12-26 Armo Biosciences, Inc. Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
US11827877B2 (en) 2018-06-28 2023-11-28 Crispr Therapeutics Ag Compositions and methods for genomic editing by insertion of donor polynucleotides
EA202190094A1 (en) 2018-06-29 2021-04-21 Бёрингер Ингельхайм Интернациональ Гмбх ANTIBODIES AGAINST CD40 FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASE
TWI709562B (en) 2018-07-06 2020-11-11 美商輝瑞股份有限公司 Manufacturing process and intermediates for a pyrrolo〔2,3-d〕pyrimidine compound and use thereof
CA3105988A1 (en) 2018-07-11 2020-01-16 Abhishek Datta High-affinity, isoform-selective tgf.beta.1 inhibitors and use thereof
EP4019046A1 (en) 2018-07-11 2022-06-29 Scholar Rock, Inc. Isoform selective tgfbeta1 inhibitors and use thereof
TW202019957A (en) 2018-07-11 2020-06-01 美商供石公司 Tgfβ1 inhibitors and use thereof
MA53160A (en) 2018-07-20 2021-05-26 Pf Medicament RECEIVER FOR VISTA
US20210348162A1 (en) 2018-08-16 2021-11-11 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the lect2 gene
US20220023450A1 (en) * 2018-09-11 2022-01-27 Memorial Sloan Kettering Cancer Center Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use
WO2020068557A1 (en) 2018-09-25 2020-04-02 BioLegend, Inc. Anti-tlr9 agents and compositions and methods for making and using the same
EP3856206A1 (en) 2018-09-27 2021-08-04 Phosphogam, Inc. Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells
WO2020065409A2 (en) 2018-09-28 2020-04-02 Lyvgen Biopharma Co., Ltd. Anti-cd40 binding molecules having engineered fc domains and therapeutic uses thereof
MA53859A (en) 2018-10-10 2022-01-19 Boehringer Ingelheim Int METHOD OF MEMBRANE GAS TRANSFER IN A HIGH-DENSITY BIOREACTOR CULTURE
WO2020077212A1 (en) 2018-10-11 2020-04-16 Amgen Inc. Downstream processing of bispecific antibody constructs
US11427591B2 (en) 2018-10-17 2022-08-30 Insilico Medicine Ip Limited Kinase inhibitors
US20210380669A1 (en) 2018-10-23 2021-12-09 Scholar Rock, Inc. Rgmc-selective inhibitors and use thereof
CN112955252B (en) * 2018-10-26 2023-11-21 康涅狄格大学 Continuous processing system and method for internal and external modification of nanoparticles
MX2021005116A (en) 2018-11-02 2021-07-15 Cytomx Therapeutics Inc Activatable anti-cd166 antibodies and methods of use thereof.
EP3883928A4 (en) 2018-11-22 2022-06-29 Qilu Regor Therapeutics Inc. Glp-1r agonists and uses thereof
CN113454216A (en) 2018-11-29 2021-09-28 旗舰先锋创新V股份有限公司 Methods of modulating RNA
MX2021006429A (en) 2018-12-06 2021-07-15 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof.
US11793834B2 (en) 2018-12-12 2023-10-24 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use
EP3914694A1 (en) 2019-01-22 2021-12-01 Massachusetts Institute of Technology In vitro human blood brain barrier
JP2020117502A (en) 2019-01-28 2020-08-06 ファイザー・インク Method of treating signs and symptoms of osteoarthritis
TW202043267A (en) 2019-01-30 2020-12-01 美商供石公司 Ltbp complex-specific inhibitors of tgfβ and uses thereof
AU2020222083B2 (en) 2019-02-15 2022-11-17 Pfizer Inc. Crystalline pyrimidinyl-3,8-diazabicyclo(3.2.1)octanylmethanone compound and use thereof
US20220135663A1 (en) 2019-02-18 2022-05-05 Pfizer Inc. Method of treatment of Chronic Low Back Pain
CN113874394B (en) 2019-02-20 2024-01-19 和铂抗体有限公司 Antibodies to
US11739078B2 (en) 2019-02-22 2023-08-29 Insilico Medicine Ip Limited Methods of inhibiting kinases
EP3930761A1 (en) 2019-02-26 2022-01-05 CytomX Therapeutics, Inc. Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies
US20200283796A1 (en) 2019-03-05 2020-09-10 Massachusetts Institute Of Technology Dna launched rna replicon system (drep) and uses thereof
BR112021017637A8 (en) 2019-03-08 2022-08-16 Massachusetts Inst Technology SYNTHETIC ONCOLYTIC VIRUS, PHARMACEUTICAL COMPOSITION, AND METHOD TO TREAT CANCER
EP3947441A1 (en) 2019-03-27 2022-02-09 UMC Utrecht Holding B.V. Engineered iga antibodies and methods of use
AR118536A1 (en) 2019-04-01 2021-10-20 Genentech Inc COMPOSITIONS AND METHODS TO STABILIZE FORMULATIONS CONTAINING PROTEIN
EP3947367A1 (en) 2019-04-02 2022-02-09 Array Biopharma, Inc. Protein tyrosine phosphatase inhibitors
EP3990452A1 (en) 2019-06-28 2022-05-04 Pfizer Inc. 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
TW202115086A (en) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk inhibitors
LT6699B (en) 2019-07-15 2020-02-10 UAB "Valentis" Method for production of proliposomes by using up to 5% ethanol and the use thereof for encapsulation of lipophilic substances
CN112300279A (en) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 Methods and compositions directed to anti-CD 73 antibodies and variants
EP4025694A1 (en) 2019-09-03 2022-07-13 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the lect2 gene
CN114650844A (en) 2019-09-23 2022-06-21 西托姆克斯治疗公司 anti-CD 47 antibodies, activatable anti-CD 47 antibodies, and methods of use thereof
WO2021062092A1 (en) 2019-09-26 2021-04-01 Massachusetts Institute Of Technology Trans-activated functional rna by strand displacement and uses thereof
WO2021062323A1 (en) 2019-09-26 2021-04-01 Stcube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
WO2021062096A1 (en) 2019-09-26 2021-04-01 Massachusetts Institute Of Technology Microrna-based logic gates and uses thereof
WO2021067526A1 (en) 2019-10-02 2021-04-08 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
US20220389429A1 (en) 2019-10-04 2022-12-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing ugt1a1 gene expression
TWI771766B (en) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 Diacylglycerol acyltransferase 2 inhibitor
CA3153932A1 (en) 2019-10-07 2021-04-15 Jonathan Kipnis Modulating lymphatic vessels in neurological disease
WO2021072277A1 (en) 2019-10-09 2021-04-15 Stcube & Co. Antibodies specific to glycosylated lag3 and methods of use thereof
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. Methods of treating an eye disorder
US20240092935A1 (en) 2019-10-11 2024-03-21 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
JP2023501912A (en) 2019-10-21 2023-01-20 ライゼン ファーマシューティカルズ アーゲー Compositions containing DHODH inhibitors for the treatment of acute myeloid leukemia
EP4051796A1 (en) 2019-11-01 2022-09-07 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajb1-prkaca fusion gene expression
CA3163979A1 (en) 2019-12-10 2021-06-17 Pfizer Inc. Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d] imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt
IL294650A (en) 2020-01-11 2022-09-01 Scholar Rock Inc Tgfbeta inhibitors and use thereof
WO2021142448A2 (en) 2020-01-11 2021-07-15 Scholar Rock,Inc. Tgf-beta inhibitors and use thereof
US20230076768A1 (en) 2020-01-14 2023-03-09 Synthekine, Inc. IL2 Orthologs and Methods of Use
CN115427447A (en) 2020-01-17 2022-12-02 百进生物科技公司 anti-TLR 7 agents and compositions and methods of making and using the same
WO2021151079A1 (en) 2020-01-24 2021-07-29 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
CN115427571A (en) 2020-02-10 2022-12-02 阿尔尼拉姆医药品有限公司 Compositions and methods for silencing VEGF-A expression
JP2022058085A (en) 2020-02-24 2022-04-11 ファイザー・インク Combination of inhibitors of diacylglycerol acyltransferase 2 and inhibitors of acetyl-coa carboxylase
AU2021232062A1 (en) 2020-03-06 2022-09-29 Colorado State University Research Foundation Production of vaccines comprising inactivated SARS-CoV-2 viral particles
CA3174908A1 (en) 2020-03-09 2021-09-16 Pfizer Inc. Fusion proteins and uses thereof
GB202003632D0 (en) 2020-03-12 2020-04-29 Harbour Antibodies Bv SARS-Cov-2 (SARS2, COVID-19) antibodies
US20230095383A1 (en) 2020-03-17 2023-03-30 Dst Pharma, Inc. Methods and compositions for treating viral infections
KR20220158031A (en) 2020-03-26 2022-11-29 피엘엑스 옵코 인코포레이티드 Pharmaceutical carrier capable of pH dependent reconstitution and method of manufacturing and using the same
BR112022017578A2 (en) 2020-03-27 2022-10-18 Pfizer TREATMENT OF TYPE 2 DIABETES OR OBESITY OR OVERWEIGHT WITH 2-[(4-{6-[(4-CYANO-2-FLUOROBENZYL)OXY]PYRIDIN-2-IL}PIPERIDIN-1-IL)METHYL]-1-[ (2S)-OXETAN-2-ILMETHYL]-1H-BENZIMIDAZOL-6-CARBOXYLIC OR A PHARMACEUTICAL SALT THEREOF
US20230190785A1 (en) 2020-03-30 2023-06-22 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajc15 gene expression
US20230295622A1 (en) 2020-04-06 2023-09-21 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing myoc expression
CN116134135A (en) 2020-04-07 2023-05-16 阿尔尼拉姆医药品有限公司 Compositions and methods for silencing SCN9A expression
EP4132931A1 (en) 2020-04-08 2023-02-15 Pfizer Inc. Crystalline forms of 3-cyano-1-[4-[6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1h-pyrazol-1-yl]cyclobutaneacetonitrile, and use thereof
CN115605229A (en) 2020-04-24 2023-01-13 米伦纽姆医药公司（Us） anti-CD 19 antibodies and uses thereof
EP4146688A1 (en) 2020-05-06 2023-03-15 CRISPR Therapeutics AG Mask peptides and masked anti-ptk7 antibodies comprising such
AU2021271317A1 (en) 2020-05-15 2023-01-19 Crispr Therapeutics Ag Messenger RNA encoding Cas9 for use in genome-editing systems
EP4153746A1 (en) 2020-05-21 2023-03-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting marc1 gene expression
JP2023527997A (en) 2020-05-27 2023-07-03 キル・レガー・セラピューティクス・インコーポレーテッド Salts and crystal forms of GLP-1R agonists and uses thereof
CA3186348A1 (en) 2020-06-09 2021-12-16 Pfizer Inc. Spiro compounds as melanocortin 4 receptor antagonists and uses thereof
CA3187966A1 (en) 2020-06-26 2021-12-30 Pfizer Inc. Methods of treating inflammatory bowel disease with tl1a antibodies
WO2022006562A1 (en) 2020-07-03 2022-01-06 Dana-Farber Cancer Institute, Inc. Multispecific coronavirus antibodies
PE20231565A1 (en) 2020-07-17 2023-10-04 Pfizer THERAPEUTIC ANTIBODIES AND THEIR USES
WO2022020811A1 (en) 2020-07-24 2022-01-27 Strand Therapeutics, Inc. Lipidnanoparticle comprising modified nucleotides
EP4188552A2 (en) 2020-07-28 2023-06-07 Jazz Pharmaceuticals Ireland Limited Fused bicyclic raf inhibitors and methods for use thereof
IL300110A (en) 2020-07-28 2023-03-01 Jazz Pharmaceuticals Ireland Ltd Chiral synthesis of fused bicyclic raf inhibitors
JP2023537005A (en) 2020-08-05 2023-08-30 シンセカイン インコーポレイテッド IL10 receptor binding molecules and methods of use
EP4192863A2 (en) 2020-08-05 2023-06-14 Synthekine, Inc. Il2rg binding molecules and methods of use
US20230272090A1 (en) 2020-08-05 2023-08-31 Sandro Vivona Il2rb binding molecules and methods of use
WO2022031869A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Gp130 binding molecules and methods of use
AR123156A1 (en) 2020-08-06 2022-11-02 Qilu Regor Therapeutics Inc GLP-1R AGONISTS AND THEIR USES
WO2022036041A1 (en) 2020-08-14 2022-02-17 Kite Pharma, Inc Improving immune cell function
AU2021340793A1 (en) 2020-09-14 2023-05-11 Vor Biopharma Inc. Single domain antibodies against cd33
US20220089759A1 (en) 2020-09-21 2022-03-24 Boehringer Ingelheim International Gmbh Use of anti-cd40 antibodies for treatment of inflammatory conditions
EP4225794A1 (en) 2020-10-06 2023-08-16 Xencor, Inc. Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle)
CN116710446A (en) 2020-10-14 2023-09-05 上海齐鲁锐格医药研发有限公司 Crystal forms of GLP-1R agonist and application thereof
WO2022093641A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2a agents and compositions and methods for making and using the same
WO2022093640A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2c agents and compositions and methods for making and using the same
US11058637B1 (en) * 2020-11-25 2021-07-13 King Abdulaziz University Surface-modified emulsomes for intranasal delivery of drugs
CA3200234A1 (en) 2020-11-25 2022-06-02 Daryl C. Drummond Lipid nanoparticles for delivery of nucleic acids, and related methods of use
JP2024505790A (en) 2020-12-18 2024-02-08 モメンタ ファーマシューティカルズ インコーポレイテッド Antibodies against integrin alpha 11 beta 1
CN116917309A (en) 2021-01-08 2023-10-20 斯特兰德生物科技公司 Expression constructs and uses thereof
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
EP4288457A2 (en) 2021-02-05 2023-12-13 Boehringer Ingelheim International GmbH Anti-il1rap antibodies
JP2024508818A (en) 2021-02-24 2024-02-28 インシリコ メディシン アイピー リミテッド Analogs for the treatment of diseases
AU2022234333A1 (en) 2021-03-11 2023-09-28 Kite Pharma, Inc. Improving immune cell function
WO2022195504A1 (en) 2021-03-19 2022-09-22 Pfizer Inc. Method of treating osteoarthritis pain with an anti ngf antibody
EP4314065A1 (en) 2021-03-22 2024-02-07 Novimmune S.A. Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
IL305828A (en) 2021-03-22 2023-11-01 Novimmune Sa Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022215054A1 (en) 2021-04-09 2022-10-13 Takeda Pharmaceutical Company Limited Antibodies targeting complement factor d and uses therof
AU2022261124A1 (en) 2021-04-22 2023-10-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer
WO2022232035A1 (en) 2021-04-26 2022-11-03 Millennium Pharmaceuticals, Inc. Anti-adgre2 antibodies and uses thereof
IL307939A (en) 2021-04-26 2023-12-01 Millennium Pharm Inc Anti-clec12a antibodies and uses thereof
WO2022235940A1 (en) 2021-05-06 2022-11-10 Dana-Farber Cancer Institute, Inc. Antibodies against alk and methods of use thereof
WO2022245859A1 (en) 2021-05-17 2022-11-24 Curia Ip Holdings, Llc Sars-cov-2 spike protein antibodies
US20230115257A1 (en) 2021-05-17 2023-04-13 Curia Ip Holdings, Llc Sars-cov-2 spike protein antibodies
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
CA3221555A1 (en) 2021-06-23 2022-12-29 Kimberly LONG A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
WO2023283403A2 (en) 2021-07-09 2023-01-12 Alnylam Pharmaceuticals, Inc. Bis-rnai compounds for cns delivery
US20230048743A1 (en) 2021-07-12 2023-02-16 Genentech Inc. Structures for Reducing Antibody-Lipase Binding
WO2023288277A1 (en) 2021-07-14 2023-01-19 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgfb1 and uses thereof
WO2023007374A1 (en) 2021-07-27 2023-02-02 Pfizer Inc. Method of treatment of cancer pain with tanezumab
GB202111759D0 (en) 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles
GB202111758D0 (en) 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A
GB202111757D0 (en) 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A
WO2023031741A1 (en) 2021-08-31 2023-03-09 Pfizer Inc. Solid forms of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt
WO2023034901A1 (en) 2021-09-01 2023-03-09 The Broad Institute, Inc. Tumor avatar vaccine compositions and uses thereof
GB202112935D0 (en) 2021-09-10 2021-10-27 Harbour Antibodies Bv Sars-cov-2 (sars2, covid-19) heavy chain only antibodies
WO2023036982A1 (en) 2021-09-10 2023-03-16 Harbour Antibodies Bv Anti-sars2-s antibodies
TW202330612A (en) 2021-10-20 2023-08-01 日商武田藥品工業股份有限公司 Compositions targeting bcma and methods of use thereof
WO2023077148A1 (en) 2021-11-01 2023-05-04 Tome Biosciences, Inc. Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
WO2023081471A1 (en) 2021-11-05 2023-05-11 Dana-Farber Cancer Institute, Inc. Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof
WO2023097024A1 (en) 2021-11-24 2023-06-01 Dana-Farber Cancer Institute, Inc. Antibodies against ctla-4 and methods of use thereof
WO2023100061A1 (en) 2021-12-01 2023-06-08 Pfizer Inc. 3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure
WO2023105387A1 (en) 2021-12-06 2023-06-15 Pfizer Inc. Melanocortin 4 receptor antagonists and uses thereof
WO2023105371A1 (en) 2021-12-08 2023-06-15 Array Biopharma Inc. Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide
WO2023111817A1 (en) 2021-12-17 2023-06-22 Pfizer Inc. Crystalline forms of [(1r,5s,6r)-3-{2-[(2s)-2-methylazetidin-1-yl]-6-(trifluoromethyl) pyrimidin-4-yl}-3-azabicyclo[3.1.0]hex-6-yl]acetic acid
WO2023114544A1 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Antibodies and uses thereof
WO2023114543A2 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Platform for antibody discovery
WO2023122764A1 (en) 2021-12-22 2023-06-29 Tome Biosciences, Inc. Co-delivery of a gene editor construct and a donor template
WO2023178357A1 (en) 2022-03-18 2023-09-21 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules and methods of use thereof
WO2023201238A1 (en) 2022-04-11 2023-10-19 Vor Biopharma Inc. Binding agents and methods of use thereof
WO2023205744A1 (en) 2022-04-20 2023-10-26 Tome Biosciences, Inc. Programmable gene insertion compositions
WO2023212618A1 (en) 2022-04-26 2023-11-02 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
WO2023215831A1 (en) 2022-05-04 2023-11-09 Tome Biosciences, Inc. Guide rna compositions for programmable gene insertion
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
WO2023225670A2 (en) 2022-05-20 2023-11-23 Tome Biosciences, Inc. Ex vivo programmable gene insertion
WO2023228023A1 (en) 2022-05-23 2023-11-30 Pfizer Inc. Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof
WO2023235852A1 (en) 2022-06-03 2023-12-07 Zenas Biopharma, Inc. Methods and compositions for treating igg4- related diseases
WO2024020051A1 (en) 2022-07-19 2024-01-25 BioLegend, Inc. Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
WO2024030850A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable substrates and methods of use thereof
WO2024030858A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable substrates and methods of use thereof
WO2024030829A1 (en) 2022-08-01 2024-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
WO2024030847A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
WO2024030843A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
WO2024030845A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
WO2024039670A1 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against cldn4 and methods of use thereof
WO2024039672A2 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof
WO2024040114A2 (en) 2022-08-18 2024-02-22 BioLegend, Inc. Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
WO2024059165A1 (en) 2022-09-15 2024-03-21 Alnylam Pharmaceuticals, Inc. 17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993754A (en) * 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4426330A (en) * 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
JPS60100516A (en) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd Preparation of sustained release microcapsule
US4885172A (en) * 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
IE58981B1 (en) * 1985-10-15 1993-12-15 Vestar Inc Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles
US4797285A (en) * 1985-12-06 1989-01-10 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Lipsome/anthraquinone drug composition and method
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
US4920016A (en) * 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4863739A (en) * 1987-05-19 1989-09-05 Board Of Regents, The University Of Texas System Liposome compositions of anthracycline derivatives
JPH0696636B2 (en) * 1988-03-30 1994-11-30 富士写真フイルム株式会社 2,4-bis (o-methoxypolyethylene glycol) -6-cholesteryl-S-triazine compound
JPH0720857B2 (en) * 1988-08-11 1995-03-08 テルモ株式会社 Liposome and its manufacturing method
AU616040B2 (en) * 1988-08-11 1991-10-17 Terumo Kabushiki Kaisha Agents for inhibiting adsorption of proteins on the liposome surface
GB8824593D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) * 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US6673364B1 (en) 1995-06-07 2004-01-06 The University Of British Columbia Liposome having an exchangeable component
US6734171B1 (en) 1997-10-10 2004-05-11 Inex Pharmaceuticals Corp. Methods for encapsulating nucleic acids in lipid bilayers
US10758329B1 (en) 2019-08-20 2020-09-01 Raymond L. Wright, III Hydrating mouth guard

Also Published As

Publication number Publication date
EP0496813A1 (en) 1992-08-05
IL96069A (en) 1995-12-08
IL96070A0 (en) 1991-07-18
ATE122229T1 (en) 1995-05-15
DE69019366T2 (en) 1995-10-05
DK0496835T3 (en) 1995-07-17
AU6898291A (en) 1991-05-16
KR0134982B1 (en) 1998-04-22
JP2889549B2 (en) 1999-05-10
EP0496835A1 (en) 1992-08-05
NO921213D0 (en) 1992-03-27
AU642679B2 (en) 1993-10-28
NO1999003I1 (en) 1999-02-23
EP0496813B1 (en) 1994-12-14
JP2667051B2 (en) 1997-10-22
HK14097A (en) 1997-02-14
ES2071976T3 (en) 1995-07-01
WO1991005546A1 (en) 1991-05-02
AU654120B2 (en) 1994-10-27
KR920703012A (en) 1992-12-17
NL960031I1 (en) 1997-03-03
JP3921050B2 (en) 2007-05-30
JP2001181214A (en) 2001-07-03
JP3571335B2 (en) 2004-09-29
CA2067178C (en) 1997-03-25
NL960031I2 (en) 2005-04-01
DE69015207D1 (en) 1995-01-26
NO921214D0 (en) 1992-03-27
NO921213L (en) 1992-06-04
LU88854I2 (en) 1997-03-11
CA2067133C (en) 1998-07-21
IL96069A0 (en) 1991-07-18
FI105151B (en) 2000-06-30
NO921214L (en) 1992-06-01
DE69019366D1 (en) 1995-06-14
GR3017060T3 (en) 1995-11-30
FI921764A0 (en) 1992-04-21
WO1991005545A1 (en) 1991-05-02
US5213804A (en) 1993-05-25
NO304637B1 (en) 1999-01-25
JPH101431A (en) 1998-01-06
FI921764A (en) 1992-04-21
EP0496835B1 (en) 1995-05-10
US5013556A (en) 1991-05-07
ATE115401T1 (en) 1994-12-15
DE19675048I2 (en) 2009-05-28
IL96070A (en) 1995-03-30
JPH05505173A (en) 1993-08-05
FI921763A (en) 1992-04-21
KR920703013A (en) 1992-12-17
JPH05501264A (en) 1993-03-11
FI921763A0 (en) 1992-04-21
DE69015207T2 (en) 1995-05-04
AU6637490A (en) 1991-05-16
CA2067178A1 (en) 1991-04-21

Similar Documents

Publication Publication Date Title
CA2067133A1 (en) Liposome Microreservoir Composition and Method
EP0662820A1 (en) Compositions for treatmewnt of inflamed tissues.
EP0632719A1 (en) Method of treatment of infected tissues.
US4873088A (en) Liposome drug delivery method and composition
KR950004885B1 (en) Pharmaceutical composition used for the treatment of glaucoma containing acetyl d-carnitine
CA2041579A1 (en) Dosage form
CA2024502A1 (en) Dosage form for administering oral hypoglycemic glipizide
PL306421A1 (en) Controlled release morphine salt containing preparation
CA2034096A1 (en) Controlled absorption naproxen formulation for once-daily administration
IE871981L (en) Programmed release formulation.
CA2014889A1 (en) Intra-rectal pharmaceutical foam compositions
AU684053B2 (en) Compositions of L-DOPA esters
EP0724885A4 (en) Pernasal composition and pernasal preparation containing the same
CA2009593A1 (en) Medicament containing dihydrolipoic acid as active substance
EP0830369A4 (en) Novel nor-pregnanes for inducing hypothalamic effects
GEP20002229B (en) Synthetic Membrane Vesicles, Method for Obtaining and Application of the Same
EP0412554A3 (en) Sustained-release preparation for administration into brain
CA2116388A1 (en) Treatment for viral diseases
WO1995030435A3 (en) Compositions and treatment for multiple sclerosis
WO1991018606A3 (en) Orally active nonaddicting analgesics
EP0294914A3 (en) Nedocromil for the treatment of dermatological disorders
AU1926988A (en) Opioid analgesic liposomal delivery-release system
EP0486944A3 (en) Method of inhibiting tumor growth using xanthocillin x dimethylether
EP0399175B1 (en) PGE1 and derivatives for dermal or mucosal application
Sustained-release et al. Antiseptic: see CHLORHEXIDINE

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry